[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1651
6. Kochbati L, Bouaouina N, Hentati D, Nasr C, Besbes M, Benna F, Boussen H, Maalej M: [Medulloblastoma with extracentral nervous system metastases: clinical presentation and risk factors]. Cancer Radiother; 2006 May;10(3):107-11
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Medulloblastoma with extracentral nervous system metastases: clinical presentation and risk factors].
  • [Transliterated title] Medulloblastoma with extracentral nervous system metastases: clinical presentation and risk factors.
  • PURPOSE: Extra-central nervous system (extra-CNS) metastases are relatively unknown failure patterns in medulloblastoma.
  • The aim of this study was to analyse epidemiological, clinical and aetiopathological aspects of these extra-CNS localisations.
  • PATIENTS AND METHODS: Extra-CNS metastases were retrospectively identified in patients treated in the department of radiation therapy at Salah-Azaïz institute (ISA) for medulloblastoma.
  • These metastases were diagnosed as extra-CNS for all secondary localisations not related to other tumour aetiology.
  • RESULTS: Among 103 patients treated and followed-up in the department of radiation therapy of ISA from 1970 to 1992, 8 developed extra-CNS metastases (7.7%).
  • The mean free-interval from diagnosis of primitive tumour to extra-CNS metastases was 23 months, varying from 8 to 53 months.
  • All patients died or are in progressive disease in less than one year from the diagnosis of extra-CNS metastases.
  • CONCLUSION: Extra-CNS metastases are not rare and have a poor prognosis.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Medulloblastoma / secondary. Nervous System Neoplasms / secondary
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Male. Retrospective Studies. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16600659.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


7. Thomas X, Pavan L, Le QH: [Adult acute lymphoblastic leukemia with central nervous system involvement: an overview]. Bull Cancer; 2008 Jul-Aug;95(7):707-15
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult acute lymphoblastic leukemia with central nervous system involvement: an overview].
  • [Transliterated title] Leucémies aiguës lymphoblastiques de l'adulte avec envahissement du système nerveux central : mise au point.
  • At the time of diagnosis, central nervous system (CNS) involvement is identified in less than 10% of adult acute lymphoblastic leukemia (ALL).
  • CNS disease at presentation does not appear to be an independent poor prognostic factor.
  • In CNS leukemia, innovative treatments and alternative delivery techniques are, however, warranted.
  • Outcome in such patients is a reflection of an aggressive systemic and CNS-directed therapy.
  • However, CNS toxicity represents the dose-limiting side effect of treatment.
  • With effective CNS prophylaxis including intrathecal chemotherapy, high-dose systemic administration of certain agents and cranial irradiation, most adults with ALL without CNS disease at diagnosis may remain free of CNS leukemia.
  • CNS involvement at the time of relapse occurs in 1 to 15% of cases.
  • Adult ALL with CNS recurrence remains of poor prognosis and is generally associated with a systemic and medullary relapse.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Central Nervous System Neoplasms / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Cytarabine / adverse effects. Cytarabine / therapeutic use. Humans. Meningeal Neoplasms. Methotrexate / adverse effects. Methotrexate / therapeutic use. Prognosis. Radiotherapy / adverse effects. Recurrence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18755650.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 109
  •  go-up   go-down


8. Moulignier A: [HIV and the central nervous system]. Rev Neurol (Paris); 2006 Jan;162(1):22-42
HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [HIV and the central nervous system].
  • [Transliterated title] Atteintes du système nerveux central et infection par le VIH-1.
  • Central nervous system complications are common in HIV-1 infected patients and occur either as a result of concomitant immunosuppression (opportunistic infections, lymphoma and tumors), as a primary manifestation of HIV infection, or as an adverse effect of therapy (immune restoration and toxicity).
  • [MeSH-major] Central Nervous System Diseases / etiology. Encephalitis / etiology. HIV Infections / complications
  • [MeSH-minor] AIDS Dementia Complex / diagnosis. AIDS Dementia Complex / epidemiology. AIDS Dementia Complex / etiology. AIDS Dementia Complex / therapy. AIDS-Related Opportunistic Infections / diagnosis. AIDS-Related Opportunistic Infections / epidemiology. AIDS-Related Opportunistic Infections / etiology. AIDS-Related Opportunistic Infections / therapy. Adult. Animals. Brain Ischemia / etiology. Brain Neoplasms / diagnosis. Brain Neoplasms / epidemiology. Brain Neoplasms / etiology. Brain Neoplasms / therapy. Child. Cytomegalovirus Infections / complications. Cytomegalovirus Infections / epidemiology. Disease Susceptibility. Encephalitis, Viral / diagnosis. Encephalitis, Viral / epidemiology. Encephalitis, Viral / etiology. Encephalitis, Viral / therapy. Humans. Immunocompromised Host. Leukoencephalopathy, Progressive Multifocal / diagnosis. Leukoencephalopathy, Progressive Multifocal / epidemiology. Leukoencephalopathy, Progressive Multifocal / etiology. Leukoencephalopathy, Progressive Multifocal / therapy. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / epidemiology. Lymphoma, AIDS-Related / etiology. Lymphoma, AIDS-Related / therapy. Magnetic Resonance Imaging. Meningitis, Cryptococcal / diagnosis. Meningitis, Cryptococcal / epidemiology. Meningitis, Cryptococcal / etiology. Meningitis, Cryptococcal / therapy. Middle Aged. Myelitis, Transverse / diagnosis. Myelitis, Transverse / epidemiology. Myelitis, Transverse / etiology. Myelitis, Transverse / therapy. Neurosyphilis / diagnosis. Neurosyphilis / epidemiology. Neurosyphilis / etiology. Neurosyphilis / therapy. Toxoplasmosis, Cerebral / diagnosis. Toxoplasmosis, Cerebral / epidemiology. Toxoplasmosis, Cerebral / etiology. Tuberculosis / diagnosis. Tuberculosis / epidemiology. Tuberculosis / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Encephalitis.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16446621.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 114
  •  go-up   go-down


9. Crawford JR, Santi MR, Cornelison R, Sallinen SL, Haapasalo H, MacDonald TJ: Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors. J Neurooncol; 2009 Oct;95(1):49-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors.
  • The purpose is to determine the incidence of active and latent human herpesvirus-6 (HHV-6) infection in a large cohort of adult primary and recurrent CNS tumors.
  • We screened a tissue microarray (TMA) containing more than 200 adult primary and recurrent CNS tumors with known clinical information for the presence of HHV-6 DNA by in situ hybridization (ISH) and protein by immunohistochemistry (IHC).
  • One hundred six of 224 (47%) CNS tumors were positive for HHV-6 U57 Major Capsid Protein (MCP) gene by ISH compared to 0/25 non tumor control brain (P = 0.001).
  • Fourteen of 30 (47%) tumors were HHV-6 MCP positive by nested PCR compared to 0/25 non-tumor brain controls (P = 0.001), revealing HHV-6 Variant A in 6 of 14 samples.
  • HHV-6A/B early (p41) and late (gp116/64/54) antigens were detected by IHC in 66 of 277 (24%) (P = 0.003) and 84 of 282 (35%) (P = 0.002) tumors, respectively, suggesting active infection.
  • Glial tumors were 3 times more positive by IHC compared to non glial tumors for both HHV-6 gp116/64/54 (P = 0.0002) and HHV-6 p41 (P = 0.004).
  • HHV-6 early and late antigens are detected in adult primary and recurrent CNS tumors more frequently in glial tumors.
  • We hypothesize that the glial-tropic features of HHV-6 may play an important modifying role in tumor biology that warrants further investigation.
  • [MeSH-major] Antigens, Viral. Central Nervous System Neoplasms / genetics. Central Nervous System Neoplasms / virology. Glioma / genetics. Glioma / virology. Herpesvirus 6, Human / isolation & purification
  • [MeSH-minor] Adult. Antigens, CD / metabolism. CD48 Antigen. Capsid Proteins / genetics. Capsid Proteins / metabolism. Humans. Survival Analysis. Viral Envelope Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19424665.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K12NS052159-01A
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Viral; 0 / CD48 Antigen; 0 / Capsid Proteins; 0 / Viral Envelope Proteins
  •  go-up   go-down


10. Lena G, Ternier J, Paz-Paredes A, Scavarda D: [Central nervous system cavernomas in children]. Neurochirurgie; 2007 Jun;53(2-3 Pt 2):223-37

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Central nervous system cavernomas in children].
  • [Transliterated title] Cavernomes du système nerveux central chez l'enfant.
  • CLINICAL PRESENTATION: In children, hemorrhage is a common manifestation with an incidence varying from 27.3 to 78% versus 8 to 37% in adult patients.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. Hemangioma, Cavernous, Central Nervous System / epidemiology
  • [MeSH-minor] Adolescent. Cerebral Hemorrhage / etiology. Child. Child, Preschool. Epilepsy / etiology. Female. Headache / etiology. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Male. Neurologic Examination. Neurosurgical Procedures. Retrospective Studies. Sex Characteristics. Sex Factors. Spinal Cord Neoplasms / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17507057.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 79
  •  go-up   go-down


11. Murray G, Jiménez L, Báez F, Colón-Castillo LE, Brau RH: Descriptive profile of surgically-confirmed adult central nervous system tumors in Puerto Rico. P R Health Sci J; 2009 Dec;28(4):317-28

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Descriptive profile of surgically-confirmed adult central nervous system tumors in Puerto Rico.
  • INTRODUCTION: Published studies regarding the incidence of central nervous system (CNS) tumors in Puerto Rico (PR) are exceedingly rare.
  • The general understanding is that the incidence of these tumors in Puerto Rico is similar to the one found in the United States of America (USA).
  • The objective of this study is to describe the specific profile of all the CNS tumors that are surgically intervened in Puerto Rico, through the creation of a database.
  • METHODS: A retrospective analysis of all the surgical procedures from January 1, 2002 to May 31, 2006 for adult CNS tumors in Puerto Rico was performed.
  • The information was organized to form a database of all the CNS neoplasms.
  • RESULTS: A total of 1,018 procedures for CNS tumors were performed on 1,005 patients.
  • The incidence rate of surgically intervened CNS tumors in Puerto Rico is 6 per 100,000 people.
  • CNS tumors were more common in women than in men (58% vs. 42%), respectively.
  • CONCLUSIONS: Our results reflect a unique histopathological distribution of operated CNS tumors in Puerto Rico.
  • In this series, primary tumors are more common than metastatic tumors.
  • Benign histological tumors were more frequent than more malignant variants.
  • Although this study reflects only the histologically diagnosed tumors, it is headway towards diagnosing the incidence of all CNS tumors in Puerto Rico.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Central Nervous System Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Puerto Rico. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999240.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Puerto Rico
  •  go-up   go-down


12. Eap C, Litré CF, Noudel R, Theret E, Duntze J, Collin P, Rousseaux P: [Primitive malignant rhabdoid tumor of the central nervous system in an adolescent. A case study]. Neurochirurgie; 2010 Oct;56(5):404-7
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primitive malignant rhabdoid tumor of the central nervous system in an adolescent. A case study].
  • [Transliterated title] Tumeur rhabdoïde du système nerveux central chez une adolescente de 16ans : à propos d'un cas.
  • Primitive malignant rhabdoid tumors of the central nervous system are rare and have a poor prognosis.
  • Adult and adolescent cases are exceptional.
  • We report the case of a 16-year-old girl who presented an intratumoral hemorrhage in a rhabdoid tumor.
  • We discuss the different therapeutic options for this patient and review the literature on this kind of tumor.
  • [MeSH-major] Brain Neoplasms. Rhabdoid Tumor

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Masson SAS.
  • (PMID = 20594960.001).
  • [ISSN] 1773-0619
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


13. Vieira Santos A, Vilela P, Mateus L, Saraiva PF, Goulão A: [Central nervous system abnormalities namely secondary brain tumors]. Acta Med Port; 2006 Nov-Dec;19(6):451-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Central nervous system abnormalities namely secondary brain tumors].
  • [Transliterated title] Tumor do sistema nervoso central secundário a radioterapia e quimioterapia.
  • The authors speculate about the possibility that this tumor may have been radiation and/or chemotherapy induced.
  • Improvement in neuroimaging techniques, in particular magnetic resonance imaging, has helped characterize Central Nervous System abnormalities, namely secondary brain tumours.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioblastoma / diagnosis. Neoplasms, Second Primary / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17583602.001).
  • [ISSN] 1646-0758
  • [Journal-full-title] Acta médica portuguesa
  • [ISO-abbreviation] Acta Med Port
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


1
Advertisement
4. Coronel F D, Gallardo V C, Gamargo G C: [Primary central nervous system lymphoma in an immunocompetent patient: report of a case]. Rev Med Chil; 2008 Apr;136(4):491-5
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary central nervous system lymphoma in an immunocompetent patient: report of a case].
  • [Transliterated title] Linfoma primario del sistema nervioso central en una paciente inmunocompetente: Caso clínico.
  • Primary central nervous system lymphoma (PCNSL) is a rare tumor.
  • The patient was treated with chemotherapy and whole brain radiotherapy, achieving complete remission of the tumor.
  • [MeSH-major] Brain Neoplasms / diagnosis. Immunocompetence. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / therapeutic use. Biopsy. Female. Humans. Magnetic Resonance Imaging. Methotrexate / therapeutic use. Prognosis. Stem Cells / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18769792.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


15. Ghannane H, Khalil T, Sakka L, Chazal J: [Analysis of a series of cavernomas of the central nervous system: 39 non operated cases, 39 operated cases, 1 dead]. Neurochirurgie; 2007 Jun;53(2-3 Pt 2):217-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of a series of cavernomas of the central nervous system: 39 non operated cases, 39 operated cases, 1 dead].
  • [Transliterated title] Analyse d'une série de cavernomes du système nerveux central: 39 cas non opérés, 39 cas opérés et un cas décédé
  • Cavernomas are vascular malformations frequently localized in the central nervous system.
  • They demonstrate the difficulties for an exact evaluation of the hemorrhagic risk in cavernomas of the central nervous system.
  • [MeSH-major] Central Nervous System Neoplasms / surgery. Hemangioma, Cavernous, Central Nervous System / surgery
  • [MeSH-minor] Adult. Brain Stem Neoplasms / epidemiology. Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / surgery. Cerebellar Neoplasms / epidemiology. Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / surgery. Cerebral Angiography. Cerebral Hemorrhage / etiology. Female. Humans. Magnetic Resonance Imaging. Male. Retrospective Studies. Risk. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17475289.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


16. Bellil S, Braham E, Limaiem F, Bellil K, Chelly I, Mekni A, Haouet S, Zitouna M, Jemel H, Khaldi M, Kchir N: [Central nervous system dysgerminoma: a clinicopathological study of 3 cases]. Tunis Med; 2009 Mar;87(3):207-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Central nervous system dysgerminoma: a clinicopathological study of 3 cases].
  • [Transliterated title] Dysgerminomes du système nerveux central: étude anatomo-clinique de 3 cas.
  • BACKGROUND: Intracranial germ cell tumors are rarely seen and typically localize in the pineal or suprasellar region.
  • The largest category of germ cell tumors is dysgerminoma.
  • CASE REPORT: We report three cases of central nervous system dysgerminomas.
  • Histologic examination and immunohistochemical study of surgical specimen were consistent with primary central nervous system dysgerminoma.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Dysgerminoma / pathology
  • [MeSH-minor] Child. Female. Humans. Male. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537016.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


17. Gyure KA: Newly defined central nervous system neoplasms. Am J Clin Pathol; 2005 Jun;123 Suppl:S3-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Newly defined central nervous system neoplasms.
  • In recent years, numerous new entities or variants of recognized central nervous system tumors have been described in the literature, and the morphologic spectrum of these neoplasms is delineated incompletely.
  • The clinicopathologic features and differential diagnosis of 4 new entities, including the chordoid glioma of the third ventricle, cerebellar liponeurocytoma, atypical teratoid/rhabdoid tumor, and papillary glioneuronal tumor, are discussed in this review.
  • [MeSH-major] Central Nervous System Neoplasms / classification. Central Nervous System Neoplasms / diagnosis
  • [MeSH-minor] Adult. Cerebellar Neoplasms / classification. Cerebellar Neoplasms / diagnosis. Child. Chordoma / classification. Chordoma / diagnosis. Diagnosis, Differential. Female. Ganglioglioma / classification. Ganglioglioma / diagnosis. Glioma / diagnosis. Glioma / pathology. Humans. Hypothalamic Neoplasms / classification. Hypothalamic Neoplasms / diagnosis. Male. Medulloblastoma / classification. Medulloblastoma / diagnosis. Prognosis. Rhabdoid Tumor / classification. Rhabdoid Tumor / diagnosis. Teratoma / classification. Teratoma / diagnosis. Third Ventricle / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16100866.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 81
  •  go-up   go-down


18. Calderón-Garcidueñas AL, Pacheco-Calleros J, Castelán-Maldonado E, Nocedal-Rustrián FC: [Primary lymphoma of the central nervous system: 20 years' experience in a referral hospital]. Rev Neurol; 2008 Jan 16-31;46(2):84-8
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary lymphoma of the central nervous system: 20 years' experience in a referral hospital].
  • [Transliterated title] Linfoma primario del sistema nervioso central: experiencia de 20 años en un hospital de referencia.
  • INTRODUCTION: Primary central nervous system lymphomas (PCNSL) are rare neoplasms. AIM.
  • RESULTS: The primary lymphomas were 1% of malignant central nervous system neoplasms.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Hospitals. Humans. Immunophenotyping. Male. Mexico. Middle Aged. Referral and Consultation. Time Factors

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18247279.001).
  • [ISSN] 1576-6578
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


19. Santosh V, Mahadevan A, Chickabasaviah YT, Bharath RD, Krishna SS: Infectious lesions mimicking central nervous system neoplasms. Semin Diagn Pathol; 2010 May;27(2):122-35
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infectious lesions mimicking central nervous system neoplasms.
  • Infections of the central nervous system (CNS) presenting as space-occupying lesions are not uncommon, particularly in developing countries.
  • Most often, infective organisms gain entry into the CNS through the hematogenous route, seed the parenchyma, and cause tissue destruction.
  • Although neoplasms are the common considerations in the presence of enhancing lesions with perilesional edema and mass effect on neuroimaging, nonneoplastic conditions-in particular, infectious lesions--can have similar imaging characteristics.
  • Biopsy diagnosis is mandatory for neoplasms, both for confirmation of diagnosis as well as grading, but most infectious lesions are managed conservatively if the diagnosis is established by noninvasive means.
  • This review discusses some of the common infectious lesions that mimic CNS neoplasms, with emphasis on pyogenic, tuberculous, and fungal lesions as well as parasitic and viral infections that present as intracranial space-occupying lesions.
  • The data of infective lesions that mimicked intracranial neoplasms, from our institute, over the last 5 years, are also presented.
  • [MeSH-major] Brain Neoplasms / diagnosis. Central Nervous System Infections / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20860316.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


20. Chtourou I, Krichen Makni S, Bahri I, Ellouze S, Khabir A, Ben Ali H, Daoud J, Boudawara TS: [Rhabdoid tumours of the central nervous system: five case studies]. Cancer Radiother; 2006 May;10(3):112-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rhabdoid tumours of the central nervous system: five case studies].
  • [Transliterated title] Les tumeurs rhabdoïdes du système nerveux central: à propos de cinq observations.
  • PURPOSE: The rhabdoid cerebral tumors were first identified by Briner et al. in 1985.
  • Such tumors are equally characterized by a critically and speedly mortal development.
  • The aim of the present study was to discuss the various anatomicoclinical and therapeutic aspects of these rare tumors.
  • Radiography through magnetic resonance revealed a heterogeneous tumor process localized respectively on the spine (one case), the insula (one case), the temporofrontal lobes (two cases) and the medulla (one case).
  • Histological examination of the tumors also showed a proliferation of giant cells with a hyaline-based cytoplasmic inclusion.
  • A recurrence of rhabdoid tumors occurred in two cases.
  • CONCLUSION: The cerebral rhabdoid malignant tumor constitutes one of the most aggressive and life-threatening intracranial tumors.
  • The optimal management of such tumors remains unknown.
  • [MeSH-major] Central Nervous System Neoplasms. Rhabdoid Tumor
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Infant. Male. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16616869.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


21. Calugaru V, Taillibert S, Lang P, Simon JM, Delattre JY, Mazeron JJ: [Neoadjuvant chemotherapy followed by radiotherapy adapted to the tumor response in the primary germinoma of the central nervous system: experience of the Pitié-Salpêtrière Hospital and review of literature]. Cancer Radiother; 2007 May;11(3):122-8
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant chemotherapy followed by radiotherapy adapted to the tumor response in the primary germinoma of the central nervous system: experience of the Pitié-Salpêtrière Hospital and review of literature].
  • [Transliterated title] Chimiothérapie néoadjuvante suivie d'une radiothérapie adaptée à la réponse tumorale dans les tumeurs germinales séminomateuses du système nerveux central: expérience de l'hôpital de la Pitié-Salpêtrière et revue de la littérature.
  • PURPOSE: Retrospective analysis of ten cases of germinoma of the central nervous system treated in Pitié-Salpêtrière Hospital, Paris.
  • PATIENTS AND METHODS: Ten male patients were treated from 1997 to 2005 for histologically verified primary seminoma of the central nervous system.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Germinoma / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Etoposide / administration & dosage. Humans. Male. Neoadjuvant Therapy. Radiotherapy Dosage. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies

  • Genetic Alliance. consumer health - Germinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17459755.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 44
  •  go-up   go-down


22. Theeler BJ, Keylock J, Yoest S, Forouhar M: Ewing's sarcoma family tumors mimicking primary central nervous system neoplasms. J Neurol Sci; 2009 Sep 15;284(1-2):186-9
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing's sarcoma family tumors mimicking primary central nervous system neoplasms.
  • Ewing's sarcoma family tumors (ESFTs) and embyronal tumors of the central nervous system are malignant primitive neuroectodermal tumors (PNETs) that can arise in the central nervous system, bones, or soft tissues.
  • When ESFTs involve the central nervous system or nearby structures the diagnosis depends on cytogenetics and immunohistochemistry as these tumors can appear otherwise histologically identical to central PNETs.
  • We present two cases of isolated central nervous system presentations of ESFTs mimicking primary central nervous system neoplasms.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Neuroectodermal Tumors, Primitive / diagnosis. Sarcoma, Ewing / diagnosis. Skull Neoplasms / diagnosis. Spinal Neoplasms / diagnosis. Temporal Bone / pathology. Thoracic Vertebrae
  • [MeSH-minor] Adolescent. Adult. Antigens, CD / analysis. Biomarkers, Tumor / analysis. Calmodulin-Binding Proteins / genetics. Cell Adhesion Molecules / analysis. Diagnosis, Differential. Diffusion Magnetic Resonance Imaging. Epidural Space. Female. Headache / etiology. Humans. Male. Memory Disorders / etiology. RNA-Binding Proteins / genetics. Spinal Cord Compression / etiology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19394051.001).
  • [ISSN] 1878-5883
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Calmodulin-Binding Proteins; 0 / Cell Adhesion Molecules; 0 / EWSR1 protein, human; 0 / RNA-Binding Proteins
  •  go-up   go-down


23. Jiang L, Marlow LA, Cooper SJ, Roemeling CV, Menke DM, Copland JA, Tun HW: Selective central nervous system tropism of primary central nervous system lymphoma. Int J Clin Exp Pathol; 2010;3(8):763-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective central nervous system tropism of primary central nervous system lymphoma.
  • Primary Central nervous system lymphoma (PCNSL) is most frequently a diffuse large B cell lymphoma (DLBCL), which is confined to the Central nervous system (CNS).
  • The lymphoma cells were shown to home to the CNS with histologic evaluations of the brain showing multiple large B cells in blood vessels consistent with intravascular large B cell lymphoma (IVL).
  • The findings are consistent with highly selective tropism of PCNSLforthe CNS and its vasculature.
  • [MeSH-major] Brain Neoplasms / pathology. Central Nervous System Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Animals. Biomarkers, Tumor / metabolism. Brain / blood supply. Brain / pathology. Cell Movement. Fatal Outcome. Female. Humans. Lymphocytes / pathology. Mice. Mice, Nude. Neoplasm Invasiveness. Neoplasm Transplantation. Osteopontin / metabolism. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Feb 1;101(3):815-21 [12393412.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1063-9 [12631608.001]
  • [Cites] Brain. 2003 May;126(Pt 5):1058-67 [12690046.001]
  • [Cites] Pathol Int. 2004 Apr;54(4):231-6 [15028023.001]
  • [Cites] Blood. 1998 Aug 1;92(3):1011-9 [9680371.001]
  • [Cites] Blood. 2006 Jan 1;107(1):190-6 [16150948.001]
  • [Cites] Hematol Oncol Clin North Am. 2006 Dec;20(6):1267-85 [17113462.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3200-10 [18184868.001]
  • [Cites] Curr Oncol Rep. 2009 Jan;11(1):73-80 [19080745.001]
  • [Cites] Blood. 2009 Jan 1;113(1):266-7; author reply 267-8 [19122120.001]
  • (PMID = 21151389.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 106441-73-0 / Osteopontin
  • [Other-IDs] NLM/ PMC2993226
  • [Keywords] NOTNLM ; Lymphoma / central nervous system / tropism
  •  go-up   go-down


24. Dungerwalla M, Osuji N, Waldman AD, Al Jehani F, Mehta A, Tailor R, Wotherspoon A, Cogill G, Matutes E: Isolated central nervous system involvement in adult T-cell lymphoma/leukaemia. Br J Haematol; 2005 Aug;130(4):511-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated central nervous system involvement in adult T-cell lymphoma/leukaemia.
  • Central nervous system (CNS) presentation of adult T-cell lymphoma/leukaemia is rare, and almost invariably associated with systemic disease.
  • We report an unusual manifestation of adult T-cell lymphoma/leukaemia, with isolated CNS involvement and unusual imaging findings.
  • [MeSH-major] Brain Neoplasms / diagnosis. Leukemia-Lymphoma, Adult T-Cell / diagnosis
  • [MeSH-minor] Adult. Antiviral Agents / therapeutic use. Disease Progression. Frontal Lobe / surgery. Humans. Interferons / therapeutic use. Magnetic Resonance Imaging. Male. Palliative Care. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Br J Haematol. 2005 Nov;131(4):557. Taylor, R [corrected to Tailor, R]
  • (PMID = 16098064.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 9008-11-1 / Interferons
  • [Number-of-references] 22
  •  go-up   go-down


25. Kadan-Lottick NS, Zeltzer LK, Liu Q, Yasui Y, Ellenberg L, Gioia G, Robison LL, Krull KR: Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers. J Natl Cancer Inst; 2010 Jun 16;102(12):881-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers.
  • BACKGROUND We sought to measure self-reported neurocognitive functioning among survivors of non-central nervous system (CNS) childhood cancers, overall and compared with a sibling cohort, and to identify factors associated with worse functioning.
  • METHODS In a retrospective cohort study, 5937 adult survivors of non-CNS cancers and 382 siblings completed a validated neuropsychological instrument with subscales in task efficiency, emotional regulation, organization, and memory.
  • Non-CNS cancer survivors and siblings were compared with multivariable linear regression and log-binomial regression.
  • RESULTS Non-CNS cancer survivors had similar or slightly worse (<0.5 standard deviation) mean test scores for all four subscales than siblings.
  • CONCLUSION A statistically and clinically significantly higher percentage of self-reported neurocognitive impairment was found among survivors of non-CNS cancers than among siblings.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2001 Apr 19;344(16):1207-13 [11309635.001]
  • [Cites] Psychosomatics. 2001 May-Jun;42(3):241-6 [11351113.001]
  • [Cites] Neurology. 2001 Jun 12;56(11):1539-45 [11402112.001]
  • [Cites] Child Neuropsychol. 2000 Sep;6(3):235-8 [11419452.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Feb;24(2):106-14 [11990695.001]
  • [Cites] Med Pediatr Oncol. 2002 May;38(5):320-8 [11979456.001]
  • [Cites] Pediatrics. 2002 Jul;110(1 Pt 1):42-52 [12093945.001]
  • [Cites] Eur J Cancer. 2003 Feb;39(3):359-65 [12565989.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1115-26 [12569614.001]
  • [Cites] Lancet Oncol. 2004 Jul;5(7):399-408 [15231246.001]
  • [Cites] Lancet. 1981 Nov 7;2(8254):1015-8 [6118478.001]
  • [Cites] Pediatrics. 1985 Apr;75(4):745-53 [3838584.001]
  • [Cites] Biometrics. 1986 Mar;42(1):121-30 [3719049.001]
  • [Cites] J Clin Oncol. 1988 Feb;6(2):315-20 [3422262.001]
  • [Cites] J Child Psychol Psychiatry. 1988 Nov;29(6):839-52 [3069852.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1989 Spring;11(1):74-86 [2496615.001]
  • [Cites] Dev Med Child Neurol. 1990 Mar;32(3):238-48 [2311827.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):145-51 [1985164.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1348-56 [2072138.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(1):13-6 [1727109.001]
  • [Cites] J Pediatr. 1992 Dec;121(6):885-9 [1447650.001]
  • [Cites] Lancet. 1994 Jul 23;344(8917):224-7 [7913156.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1712-22 [9586883.001]
  • [Cites] J Pediatr Psychol. 1998 Oct;23(5):333-40 [9782681.001]
  • [Cites] J Pediatr Psychol. 2005 Jan-Feb;30(1):65-78 [15610986.001]
  • [Cites] Pediatr Blood Cancer. 2005 Sep;45(3):281-90 [15806539.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 May-Jun;22(3):206-13 [10864051.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3858-64 [16921038.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 6;98(23):1742-5 [17148777.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):4914-21 [17971588.001]
  • [Cites] Pediatrics. 2007 Nov;120(5):e1229-36 [17974716.001]
  • [Cites] Neuropsychol Rev. 2008 Jun;18(2):121-31 [18415683.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3025-30 [18565888.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2188-97 [18792068.001]
  • [Cites] Pediatr Blood Cancer. 2009 Feb;52(2):159-64 [18680151.001]
  • [Cites] J Int Neuropsychol Soc. 2009 Jan;15(1):31-41 [19128526.001]
  • [Cites] J Clin Oncol. 2009 May 10;27(14):2308-18 [19364948.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2626-35 [19815636.001]
  • [Cites] Neuropsychology. 2009 Nov;23(6):705-17 [19899829.001]
  • [Cites] Eur J Pharmacol. 2010 Jan 10;626(1):83-6 [19835870.001]
  • [CommentIn] J Natl Cancer Inst. 2011 Apr 6;103(7):607; author reply 607-9 [21350219.001]
  • (PMID = 20458059.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / KL2 RR024138; United States / NCI NIH HHS / CA / U24-CA55727
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2886093
  •  go-up   go-down


26. Wu W, Shi JX, Cheng HL, Wang HD, Hang CH, Shi QL, Yin HX: Hemangiopericytomas in the central nervous system. J Clin Neurosci; 2009 Apr;16(4):519-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemangiopericytomas in the central nervous system.
  • Hemangiopericytomas, which are more aggressive than meningiomas, are rare in the central nervous system (CNS).
  • We analyzed the clinical, radiological and histological features and treatment of 26 patients with hemangiopericytomas in the CNS.
  • Most tumors were located in the parasagittal and falx regions.
  • The tumors were dense or mixed as assessed by CT scans, and most were homogeneously enhanced.
  • Most tumors were isointense on T1-weighted MRI, and high or mixed intensity on T2-weighted MRI; they were homogeneously or heterogeneously enhanced.
  • Histological examination indicated numerous small vascular spaces in the tumor.
  • All tumors were immunohistochemically positive for vimentin.
  • Surgical removal and post-operative radiotherapy are thus critical for the treatment of this tumor.
  • [MeSH-major] Central Nervous System Neoplasms. Hemangiopericytoma
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neurosurgical Procedures / methods. Radiotherapy. Retrospective Studies. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19246200.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


27. Buckner JC, Brown PD, O'Neill BP, Meyer FB, Wetmore CJ, Uhm JH: Central nervous system tumors. Mayo Clin Proc; 2007 Oct;82(10):1271-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system tumors.
  • Central nervous system tumors are relatively common in the United States, with more than 40,000 cases annually.
  • Although more than half of these tumors are benign, they can cause substantial morbidity.
  • Malignant primary brain tumors are the leading cause of death from solid tumors in children and the third leading cause of death from cancer in adolescents and adults aged 15 to 34 years.
  • Whereas magnetic resonance imaging helps define the anatomic extent of tumor, biopsy is often required to confirm the diagnosis.
  • Benign tumors are usually curable with surgical resection or radiation therapy including stereotactic radiation; however, most patients with malignant brain tumors benefit from chemotherapy either at the time of initial diagnosis or at tumor recurrence.
  • Metastases to the brain remain a frequent and morbid complication of solid tumors but are frequently controlled with surgery or radiation therapy.
  • Unfortunately, the mortality rate from malignant brain tumors remains high, despite initial disease control.
  • This article provides an overview of current diagnostic and treatment approaches for patients with primary and metastatic brain tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Glioma / diagnosis. Glioma / therapy. Humans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17908533.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


28. Thomas X, Le QH: Central nervous system involvement in adult acute lymphoblastic leukemia. Hematology; 2008 Oct;13(5):293-302
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system involvement in adult acute lymphoblastic leukemia.
  • Central nervous system (CNS) involvement is identified at the time of diagnosis in less than 10% of adult acute lymphoblastic leukemia (ALL).
  • CNS disease at presentation does not appear to be an independent poor prognostic factor.
  • Because of the difficulty in treating CNS leukemia, innovative treatments and alternative delivery techniques are needed.
  • The outcome in such patients is a reflection of an aggressive systemic and CNS-directed therapy.
  • However, CNS toxicity represents the dose-limiting side effect of treatment.
  • With effective CNS prophylaxis including intrathecal chemotherapy, high-dose systemic administration of certain agents and cranial irradiation, most adults with ALL without CNS disease at diagnosis may remain free of CNS leukemia.
  • Leukemic relapse remains a major therapeutic problem and CNS involvement at the time of relapse occurs in 1-15% of cases.
  • Adult ALL with CNS recurrence remains of poor prognosis and is generally associated with a systemic relapse.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Humans. Injections, Spinal. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18854093.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 95
  •  go-up   go-down


29. Maule M, Scélo G, Pastore G, Brennan P, Hemminki K, Pukkala E, Weiderpass E, Olsen JH, Tracey E, McBride ML, Brewster DH, Pompe-Kirn V, Tonita JM, Kliewer EV, Chia KS, Jonasson JG, Martos C, Magnani C, Boffetta P: Risk of second malignant neoplasms after childhood central nervous system malignant tumours: an international study. Eur J Cancer; 2008 Apr;44(6):830-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of second malignant neoplasms after childhood central nervous system malignant tumours: an international study.
  • PURPOSE: The aim of this study was to assess the risk of second malignant neoplasms (SMNs) other than central nervous system (CNS) neoplasms after childhood CNS cancer in an international multicentre study.
  • METHODS: Individual data on cases of CNS cancer in children (0-14 years) and on subsequent SMNs were obtained from 13 population-based cancer registries contributing data for different time periods in 1943-2000.
  • RESULTS: We observed 43 SMNs in 8431 CNS cancer survivors.
  • The SIRs were highest in the first 10 years after CNS cancer diagnosis.
  • The cumulative incidence of non-CNS SMNs was 3.30% (0.95-5.65%) within 45 years after a CNS cancer diagnosis.
  • CONCLUSION: This population-based study indicates that about one every 180 survivors of a childhood CNS cancer will develop a non-CNS SMN within the following 15 years.
  • The excess is higher after glioma and embryonal malignant tumour than after another CNS tumour.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Epidemiologic Methods. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Risk

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18329873.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R03 CA101442-02
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


30. Umredkar A, Bal A, Vashista RK: Atypical teratoid/rhabdoid tumour of the central nervous system in adult: case report. Br J Neurosurg; 2010 Dec;24(6):699-704

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid/rhabdoid tumour of the central nervous system in adult: case report.
  • Atypical teratoid/rhabdoid tumours (AT/RT) are aggressive neoplasms of the central nervous system occurring mainly in the paediatric population.
  • The neoplasm was localised in the left frontal region and was totally excised.
  • This unusual presentation underlines the necessity of considering this devastating neoplasm in the differential diagnosis of malignant brain tumours of adults.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Rhabdoid Tumor / pathology. Teratoma / pathology
  • [MeSH-minor] Adult. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21070155.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Giebel S, Krawczyk-Kuliś M, Adamczyk-Cioch M, Czyz A, Lech-Marańda E, Piatkowska-Jakubas B, Paluszewska M, Pałynyczko G, Piszcz J, Hołowiecki J, Polish Adult Leukemia Group: Prophylaxis and therapy of central nervous system involvement in adult acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group. Pol Arch Med Wewn; 2008 Jun;118(6):356-61
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylaxis and therapy of central nervous system involvement in adult acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group.
  • The central nervous system (CNS) is one of the most frequent extramedullary locations of adult acute lymphoblastic leukemia (ALL), affecting approximately 5% of patients at diagnosis.
  • In case of relapse, if no prophylaxis was administered, the rate of CNS involvement reaches 30-50%.
  • As the prognosis of patients with isolated or mixed CNS relapse is particularly poor, adequate prophylaxis seems critical.
  • The treatment comprises intrathecal cytostatics, cranial and spinal cord irradiation, as well as systemic chemotherapy including agents penetrating to the CNS.
  • This strategy allows a reduction in CNS relapses to less than 5% of cases.
  • Compliance to the prophylactic protocols should be one of the principles in the treatment of adult ALL.
  • [MeSH-major] Central Nervous System Neoplasms / prevention & control. Central Nervous System Neoplasms / therapy. Neoplasm Recurrence, Local. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Quality of Life

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18619191.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 28
  •  go-up   go-down


32. Darefsky AS, Dubrow R: International variation in the incidence of adult primary malignant neoplasms of the brain and central nervous system. Cancer Causes Control; 2009 Nov;20(9):1593-604
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] International variation in the incidence of adult primary malignant neoplasms of the brain and central nervous system.
  • We examined international variation in adult brain cancer incidence in 69 populations from a subset of cancer registries included in Cancer Incidence in Five Continents, Volume IX that met stringent quality standards.
  • Rates among south-central Asians and northern America blacks were half to three-fifths the rates among northern America non-Hispanic whites.
  • [MeSH-major] Brain Neoplasms / epidemiology. Spinal Cord Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Aged. Ethnic Groups. Female. Humans. Incidence. Male. Middle Aged. Registries. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19633913.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


33. Smith AB, Rushing EJ, Smirniotopoulos JG: Pigmented lesions of the central nervous system: radiologic-pathologic correlation. Radiographics; 2009 Sep-Oct;29(5):1503-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pigmented lesions of the central nervous system: radiologic-pathologic correlation.
  • Pigmented lesions of the central nervous system (CNS) are a diverse group of entities that run the gamut from benign to malignant.
  • Pigmented lesions include primary melanocytic lesions of the CNS and metastatic melanoma, as well as other CNS neoplasms that may undergo melanization, including schwannoma, medulloblastoma, and some gliomas.
  • Primary melanocytic lesions of the CNS arise from melanocytes located within the leptomeninges, and this group includes diffuse melanocytosis and meningeal melanomatosis (seen in neurocutaneous melanosis), melanocytoma, and malignant melanoma.
  • Primary melanin-containing lesions of the CNS must be differentiated from metastatic melanoma because these lesions require different patient workup and therapy.
  • Absence of a known primary malignant melanoma helps in the differential diagnosis, but an occult primary lesion outside the CNS must be sought and excluded.
  • Pigmented lesions of the CNS are uncommon, and knowledge of their imaging characteristics and pathologic features is essential for their identification.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Diagnostic Imaging / methods. Pigmentation Disorders / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Infant. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Skin Pigmentation Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2009.
  • (PMID = 19755608.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 92
  •  go-up   go-down


34. Gläsker S, Van Velthoven V: Risk of hemorrhage in hemangioblastomas of the central nervous system. Neurosurgery; 2005 Jul;57(1):71-6; discussion 71-6
MedlinePlus Health Information. consumer health - Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of hemorrhage in hemangioblastomas of the central nervous system.
  • OBJECTIVE: Hemangioblastomas are benign vascular tumors of the central nervous system.
  • Several cases of spontaneous hemorrhage within these tumors have been reported.
  • However, the risk of hemorrhage in these tumors remains unknown.
  • METHODS: To clarify the incidence of hemorrhage in hemangioblastomas, we reviewed our large clinical database of 277 patients with central nervous system hemangioblastomas for the incidence of spontaneous or perioperative hemorrhage.
  • Clinical characteristics such as tumor size, tumor location, von Hippel-Lindau disease status, and clinical symptoms before hemorrhage were correlated with hemorrhage risk.
  • The average diameter of tumors that bled was 3 cm in our series and 2.3 cm in the literature review, whereas the average diameter of hemangioblastomas in major series ranges from 0.8 to 1.1 cm.
  • An important indicator for the probability of hemorrhage is tumor size, as spontaneous or postoperative hemorrhage occurred exclusively in extraordinarily large tumors.
  • Hemangioblastomas smaller than 1.5 cm (the vast majority of these tumors) harbor virtually no risk of spontaneous hemorrhage.
  • [MeSH-major] Central Nervous System Neoplasms / physiopathology. Hemangioblastoma / physiopathology. Hemorrhage / etiology. Risk
  • [MeSH-minor] Adult. Aged. Clinical Trials as Topic. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neurosurgery / methods. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15987542.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


35. Haruki H, Tanaka S, Koga M, Kawai M, Negoro K, Kanda T: [Central nervous system leukemia mimicking rapidly progressive HTLV-1 associated myelopathy]. Nihon Ronen Igakkai Zasshi; 2009 Mar;46(2):184-7
MedlinePlus Health Information. consumer health - Spinal Cord Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Central nervous system leukemia mimicking rapidly progressive HTLV-1 associated myelopathy].
  • Adult T cell lymphoma (ATL)-like cells were seen in the CSF.
  • Direct infiltration of ATL cells to central nervous system was therefore suggested to have caused neurological abnormalities in this case.
  • One may consider central nervous system leukemia when rapidly progressive HAM-like symptoms and signs are recognized, especially without positive anti-HTLV-1 antibody in the CSF.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. HTLV-I Infections / complications. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Spinal Cord Diseases / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19491526.001).
  • [ISSN] 0300-9173
  • [Journal-full-title] Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics
  • [ISO-abbreviation] Nihon Ronen Igakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


36. Bhagavathi S, Wilson JD: Primary central nervous system lymphoma. Arch Pathol Lab Med; 2008 Nov;132(11):1830-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma.
  • Primary central nervous system lymphoma (PCNSL) is an uncommon extranodal non-Hodgkin lymphoma.
  • The differential diagnosis of PCNSL includes central nervous system gliomas, metastatic tumors, demyelinating disorders, subacute infarcts, and space-occupying lesions due to an infectious etiology.
  • Primary central nervous system lymphomas are treated with combined radiotherapies and chemotherapies.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976024.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


37. Phi JH, Park SH, Paek SH, Kim SK, Lee YJ, Park CK, Cho BK, Lee DH, Wang KC: Expression of Sox2 in mature and immature teratomas of central nervous system. Mod Pathol; 2007 Jul;20(7):742-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Sox2 in mature and immature teratomas of central nervous system.
  • This study was undertaken to investigate the expression pattern of Sox2 in mature and immature teratomas of the central nervous system.
  • Sox2 immunohistochemistry was performed in 14 cases of central nervous system teratoma: five mature, five immature teratomas, and four mixed germ cell tumors with a prominent teratoma component.
  • Since Sox2 is strongly expressed in the primitive neuroepithelial tissues of central nervous system immature teratomas, it may be a useful biomarker for the diagnosis and quantitative grading of central nervous system immature teratomas.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. HMGB Proteins / biosynthesis. Teratoma / pathology. Transcription Factors / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Fluorescent Antibody Technique. Glial Fibrillary Acidic Protein / analysis. Humans. Immunohistochemistry. Infant. Male. Microscopy, Confocal. SOXB1 Transcription Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17464316.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / HMGB Proteins; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors; 0 / Transcription Factors
  •  go-up   go-down


38. Alécio-Mattei T, Alécio-Mattei J, Aguiar PH, Ramina R: Primary central nervous system lymphomas in immunocompetent patients. Neurocirugia (Astur); 2006 Feb;17(1):46-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphomas in immunocompetent patients.
  • OBJECTIVES: Primary central nervous system lymphoma (PCNSL) is a rare pathology and is most often seen in immunodeficient patients.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / therapy. Lymphoma, B-Cell / therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunocompetence. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565780.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 32
  •  go-up   go-down


39. Kamnasaran D, Guha A: Expression of GATA6 in the human and mouse central nervous system. Brain Res Dev Brain Res; 2005 Nov 7;160(1):90-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of GATA6 in the human and mouse central nervous system.
  • The expression profile of GATA6 has been poorly defined in the central nervous system (CNS).
  • In this report, we identify GATA6 expression in the normal mouse and human CNS, using Northern blot analyses, immunohistochemistry (IHC), and immunofluorescence (IF).
  • GATA6 is expressed as a 2.2 kb transcript in the adult mouse brain and several regions of the adult human brain.
  • [MeSH-major] Astrocytes / metabolism. Central Nervous System / growth & development. Endothelial Cells / metabolism. GATA6 Transcription Factor / metabolism. Gene Expression Regulation, Developmental / genetics. Neurons / metabolism
  • [MeSH-minor] Aging / genetics. Aging / metabolism. Animals. Animals, Newborn. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Cell Differentiation / genetics. Cell Line. Choroid Plexus / metabolism. Genes, Tumor Suppressor / physiology. Glioma / genetics. Glioma / metabolism. Humans. Immunohistochemistry. Mice. Protein Isoforms / genetics. Protein Isoforms / metabolism. RNA, Messenger / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16150495.001).
  • [ISSN] 0165-3806
  • [Journal-full-title] Brain research. Developmental brain research
  • [ISO-abbreviation] Brain Res. Dev. Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / GATA6 Transcription Factor; 0 / GATA6 protein, human; 0 / Protein Isoforms; 0 / RNA, Messenger
  •  go-up   go-down


40. McMillan A: Central nervous system-directed preventative therapy in adults with lymphoma. Br J Haematol; 2005 Oct;131(1):13-21
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system-directed preventative therapy in adults with lymphoma.
  • All adult patients with Burkitt lymphoma or lymphoblastic lymphoma should receive central nervous system (CNS)-directed therapy with both intrathecal and high-dose systemic chemotherapy.
  • There is no evidence to support the routine use of prophylactic CNS-directed therapy in any specific subgroup of adult patients with 'low grade' lymphomas.
  • There are some anatomical sites where involvement by lymphoma is associated with a higher risk of CNS relapse.
  • Multivariate analyses strongly support a raised serum lactate dehydrogenase level and the involvement of more than one extranodal site as the strongest predictors of subsequent CNS relapse.
  • It is not clear how the best balance between the 'sensitivity' and 'specificity' of the choice of patients to receive CNS-directed therapy can be achieved.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / prevention & control. Lymphoma / prevention & control
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Burkitt Lymphoma / blood. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / prevention & control. Female. Humans. Injections, Spinal. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control. Prognosis. Recurrence. Risk Assessment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16173958.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.27 / L-Lactate Dehydrogenase
  • [Number-of-references] 47
  •  go-up   go-down


41. Salvati M, Caroli E, Frati A, Piccirilli M, Agrillo A, Brogna C, Occhiogrosso G, Giangaspero F: Central nervous system mesenchymal chondrosarcoma. J Exp Clin Cancer Res; 2005 Jun;24(2):317-24
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system mesenchymal chondrosarcoma.
  • Central nervous system mesenchymal chondrosarcomas are rare malignant tumors that constitute a separate entity from the classical chondrosarcoma and myxoid variant.
  • Clinical behaviour of central nervous system chondrosarcomas is still unknown.
  • We describe two rare examples of intracranial mesenchymal chondrosarcoma with a review of the literature, in an attempt to clarify the clinical characteristics, prognosis and treatment of choice of these unusual tumors.
  • Although clinical behaviour of central nervous system chondrosarcomas remains to be defined, data from our series as well as literature show that radical removal is the best therapeutic choice.
  • [MeSH-major] Brain Neoplasms / diagnosis. Chondrosarcoma, Mesenchymal / diagnosis
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents. Cartilage / pathology. Cell Differentiation. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / mortality. Central Nervous System Neoplasms / therapy. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110767.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


42. Sawada T, Kato Y, Kobayashi M: Expression of aquaporine-4 in central nervous system tumors. Brain Tumor Pathol; 2007;24(2):81-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of aquaporine-4 in central nervous system tumors.
  • Cerebral edema is associated with common brain tumors.
  • To elucidate the characterization of the expression of AQP4 and the relationship of the expression of VEGF, we investigated the expression of AQP4 in tumors of the central nervous system immunohistochemically.
  • Brain tumors and nontumorous cerebral tissue for control were evaluated by immunohistochemical staining using anti-AQP4, VEGF, CD34, and MIB-1.
  • In tumor cells, only glial tumor cells showed a positive reaction for AQP4.
  • Although endothelial cells were negative and/or weakly positive for AQP4, the positive relationship suggested the expression of VEGF in endothelial cells in neovasculature and that of AQP 4 in tumor cells.
  • APQ4 expression increased in human astrocytic tumors and edematous cerebral tissue.
  • Upregulation of APQ4 by tumor cells and reactive astroglia were major factors of cerebral edema.
  • [MeSH-major] Aquaporin 4 / biosynthesis. Brain Neoplasms / metabolism. Brain Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Astrocytes / metabolism. Brain Edema / etiology. Brain Edema / metabolism. Female. Gene Expression. Humans. Immunohistochemistry. Male. Middle Aged. Receptors, Vascular Endothelial Growth Factor / biosynthesis. Up-Regulation. Vascular Endothelial Growth Factor A / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095136.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / AQP4 protein, human; 0 / Aquaporin 4; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


43. Zhou J, Wang J, Li N, Zhang X, Zhou H, Zhang R, Ma H, Zhou X: Molecularly genetic analysis of von Hippel-Lindau associated central nervous system hemangioblastoma. Pathol Int; 2010 Jun;60(6):452-8
MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecularly genetic analysis of von Hippel-Lindau associated central nervous system hemangioblastoma.
  • Von Hippel-Lindau (VHL) disease is an autosomal dominant inherited cancer predisposition syndrome, characterized by development of a variety of neoplasms in multiple organs.
  • Central nervous system hemangioblastoma (CHB) is the most common manifestation of VHL disease.
  • The germline mutations in the VHL tumor suppressor gene are responsible for the inherited cancer predisposition syndrome.
  • To expand the VHL mutation data and to investigate the tumorigenesis of VHL-associated CNS hemangioblastoma, 24 CHB tissue samples and blood samples of 14 patients from 10 Chinese VHL families were collected and subjected to molecular genetic analysis.
  • In addition, expression of the ZAC1 tumor suppressor gene protein was studied using immunohistochemistry staining in CHB tissues with a specific polyclonal antibody.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Germ-Line Mutation / genetics. Hemangioblastoma / genetics. von Hippel-Lindau Disease / genetics
  • [MeSH-minor] Adolescent. Adult. Cell Cycle Proteins / genetics. Cell Cycle Proteins / metabolism. Child. DNA Mutational Analysis. Family Health. Female. Humans. Loss of Heterozygosity. Male. Middle Aged. Nuclear Family. Point Mutation. Transcription Factors / genetics. Transcription Factors / metabolism. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism. Von Hippel-Lindau Tumor Suppressor Protein / genetics. Von Hippel-Lindau Tumor Suppressor Protein / metabolism. Young Adult

  • Genetic Alliance. consumer health - Hemangioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518900.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / PLAGL1 protein, human; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


44. Dietlein M, Pels H, Schulz H, Staak O, Borchmann P, Schomäcker K, Fischer T, Eschner W, Pogge von Strandmann E, Schicha H, Engert A, Schnell R: Imaging of central nervous system lymphomas with iodine-123 labeled rituximab. Eur J Haematol; 2005 Apr;74(4):348-52
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of central nervous system lymphomas with iodine-123 labeled rituximab.
  • Most patients with primary central nervous system (CNS) lymphoma (PCNSL) relapse after initial response to chemotherapy or the combination of chemotherapy and irradiation.
  • As the majority of PCNSL are B-cell neoplasms expressing the CD20 antigen, treatment with the chimeric monoclonal antibody (MAb) rituximab might be reasonable.
  • Only one patient showed a very weak or questionable uptake of 123I-rituximab into tumor tissue which was ninefold lower compared with the blood-pool accumulation.
  • These data suggest that systemic MAb-based radio-immunotherapy is not feasible in patients with PCNSL because a sufficient activity in the tumor will be associated with severe hematotoxicity.
  • [MeSH-major] Antibodies, Monoclonal. Brain Neoplasms / radionuclide imaging. Lymphoma, B-Cell / radionuclide imaging. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Radioimmunodetection
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Humans. Iodine Radioisotopes. Rituximab. Tomography, Emission-Computed, Single-Photon

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Blackwell Munksgaard.
  • (PMID = 15777348.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Iodine Radioisotopes; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


45. Wadasadawala T, Trivedi S, Gupta T, Epari S, Jalali R: The diagnostic dilemma of primary central nervous system melanoma. J Clin Neurosci; 2010 Aug;17(8):1014-1017
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic dilemma of primary central nervous system melanoma.
  • Melanomas are malignant neoplasms of melanocytes developing predominantly in the skin, but occasionally arising from eyes, mucous membranes, and the central nervous system (CNS).
  • The CNS can be affected by a spectrum of melanocytic lesions ranging from diffuse neurocutaneous melanosis, to a focal and benign neoplasm (melanocytoma), and to an overtly malignant tumor (melanoma).
  • Primary melanocytic lesions involving the CNS are typically concentrated in the perimedullary and high cervical region.
  • Primary CNS melanoma cannot be reliably distinguished from metastatic melanoma on neuroimaging and histopathological characteristics alone: its diagnosis is established only after exclusion of secondary metastatic disease from a cutaneous, mucosal or retinal primary.
  • We present two patients with primary CNS melanoma and discuss relevant issues, available treatment options, and expected outcomes.
  • Awareness of disease spectrum and clinico-biological differences may be used to guide therapeutic decision-making for a patient with a proven or suspected primary CNS melanoma.
  • [MeSH-major] Brain Neoplasms / pathology. Cerebellopontine Angle / pathology. Melanoma / pathology. Parietal Lobe / pathology
  • [MeSH-minor] Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Male. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20627582.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


46. Bayraktar S, Stefanovic A, Montague N, Davis J, Murray T, Lossos IS: Central nervous system manifestations of marginal zone B-cell lymphoma. Ann Hematol; 2010 Oct;89(10):1003-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system manifestations of marginal zone B-cell lymphoma.
  • Primary or secondary central nervous system (CNS) involvement by marginal zone B-cell lymphoma (MZBCL) is rare.
  • A retrospective analysis of patients was done with MZBCL involving the CNS, diagnosed and treated at our institution between 2004 and 2010.
  • We identified 10 MZBCL patients with primary (six) or secondary (four) CNS involvement.
  • Only one patient had CNS relapse 5 years later.
  • Primary or secondary CNS involvement by MZBCL display indolent clinical behavior and have a generally favorable prognosis, underlining the importance of their differentiation from aggressive lymphomas that more commonly involve the CNS.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology
  • [MeSH-minor] Adult. Aged. Eye Neoplasms / pathology. Eye Neoplasms / therapy. Female. Humans. Male. Middle Aged. Recurrence. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20440502.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA109335; United States / NCI NIH HHS / CA / R01-CA122105
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


47. Inda MM, Castresana JS: RASSF1A promoter is highly methylated in primitive neuroectodermal tumors of the central nervous system. Neuropathology; 2007 Aug;27(4):341-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RASSF1A promoter is highly methylated in primitive neuroectodermal tumors of the central nervous system.
  • Although cancer is rare in children, primary brain tumors constitute the most frequent location of solid tumors in childhood.
  • Primitive neuroectodermal tumors (PNET) of the central nervous system can be divided into infratentorial PNET or medulloblastoma (MB), and supratentorial (sPNET) tumors.
  • The RASSF1A (Ras Association Domain Family Protein 1) gene, located at 3p21.3, is highly methylated in multiple primary tumor samples, including neuroblastoma.
  • Therefore, the inactivation of the RASSF1A gene seems to be an important step in the tumorigenesis of PNET of the central nervous sytem.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Medulloblastoma / genetics. Neuroectodermal Tumors, Primitive / genetics. Promoter Regions, Genetic. Supratentorial Neoplasms / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. DNA Methylation. Female. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17899687.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


48. Spectre G, Gural A, Amir G, Lossos A, Siegal T, Paltiel O: Central nervous system involvement in indolent lymphomas. Ann Oncol; 2005 Mar;16(3):450-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system involvement in indolent lymphomas.
  • BACKGROUND: Central nervous system (CNS) involvement, a well-recognized complication of aggressive non-Hodgkin's lymphomas (NHL), has rarely been reported in indolent lymphomas.
  • PATIENTS AND METHODS: We retrospectively reviewed the disease characteristics and clinical course in seven patients (six females, one male) with indolent B-cell lymphomas who developed CNS involvement during various stages of their illness.
  • RESULTS: The median ages at diagnosis of systemic and CNS lymphoma were 60 and 63 years, respectively.
  • Five patients achieved CNS response.
  • Three patients died of CNS disease.
  • CONCLUSIONS: CNS involvement is a rare and unexpected complication of indolent NHL, which should be considered in the differential diagnosis of patients presenting with new neurological signs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642707.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


49. Ulbright TM, Hattab EM, Zhang S, Ehrlich Y, Foster RS, Einhorn LH, Cheng L: Primitive neuroectodermal tumors in patients with testicular germ cell tumors usually resemble pediatric-type central nervous system embryonal neoplasms and lack chromosome 22 rearrangements. Mod Pathol; 2010 Jul;23(7):972-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive neuroectodermal tumors in patients with testicular germ cell tumors usually resemble pediatric-type central nervous system embryonal neoplasms and lack chromosome 22 rearrangements.
  • Primitive neuroectodermal tumors (PNETs) are one of the most frequent types of 'non-germ cell' tumor in patients with testicular germ cell tumors and have a guarded prognosis when present in metastatic sites after cisplatin-based chemotherapy.
  • Improved treatments, including targeted therapy, require understanding the biology of these neoplasms.
  • We therefore analyzed the morphologic, immunohistochemical and molecular biologic features of 14 PNETs from 14 patients with concurrent or previous testicular germ cell tumors; 12 tumors were from metastatic sites and 2 were primary in the testis.
  • Using standard light microscopic criteria for central nervous system and peripheral PNETs, we classified nine tumors as medulloepithelioma, three as medulloblastoma/supratentorial PNET, one as neuroblastic tumor with abundant neuropil and true rosettes and one as small cell embryonal tumor/PNET (Ewing sarcoma-like).
  • INI1 was diffusely and strongly positive in all tumors whereas the other stains, except for cytoplasmic WT1 (which showed substantial reactivity in most tumors), were mostly focal to negative, including CD99 (eight negative, six focal) and Fli-1 (all negative).
  • Only 1 tumor, classified as medulloepithelioma, was scored positive for chromosome 22 translocation (22% rearranged cells) and the remaining 13 were negative, including the one case that resembled peripheral PNET.
  • We conclude that PNETs derived from testicular germ cell tumors mostly resemble central nervous system PNETs and generally lack the chromosome 22 translocation of peripheral PNETs.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Multiple Primary / pathology. Neuroectodermal Tumors, Primitive, Peripheral / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Chromosomes, Human, Pair 22 / genetics. Gene Rearrangement. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Young Adult

  • Genetic Alliance. consumer health - Chromosome 22.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20348883.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


50. Uematsu Y, Fukai J, Okita R, Owai Y, Fujita K, Tanaka Y, Itakura T: Intra-axial pseudotumors in the central nervous system: clinicopathological analysis. Brain Tumor Pathol; 2010 Oct;27(2):71-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-axial pseudotumors in the central nervous system: clinicopathological analysis.
  • Intra-axial pseudotumors in the central nervous system often mimic malignant brain tumors and cause difficulty in diagnosis and treatment.
  • MRI demonstrated perifocal edema and ring-like or solid enhancement, mimicking the malignant tumors.
  • These results suggested that intra-axial pseudotumors in the central nervous system contain various kinds of pathology, and detailed clinicopathological analysis is important from the point of view of differential diagnosis.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Pseudotumor Cerebri / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain Abscess / pathology. Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Cell Count. Cerebral Angiography. Coloring Agents. Demyelinating Diseases / pathology. Female. Gliosis / pathology. Histiocytosis, Non-Langerhans-Cell / pathology. Humans. Image Processing, Computer-Assisted. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Tissue Fixation. Tomography, Emission-Computed, Single-Photon. Vasculitis, Central Nervous System / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21046308.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Coloring Agents
  •  go-up   go-down


51. Cheng YC, Lirng JF, Chang FC, Guo WY, Teng MM, Chang CY, Wong TT, Ho DM: Neuroradiological findings in atypical teratoid/rhabdoid tumor of the central nervous system. Acta Radiol; 2005 Feb;46(1):89-96
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroradiological findings in atypical teratoid/rhabdoid tumor of the central nervous system.
  • PURPOSE: To evaluate the computed tomography (CT) and magnetic resonance imaging (MRI) findings of atypical teratoid tumor/rhabdoid tumor (AT/RT) of the central nervous system (CNS).
  • MATERIAL AND METHODS: Twenty cases of CNS AT/RT have been found over the past 23 years in our hospital; these involving 11 boys and 9 girls whose mean age at diagnosis was 5.5 years.
  • However, AT/RT should still remain in the differential diagnosis of brain tumors in young children, especially those located in the cerebellar hemisphere and with eccentric cysts.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Central Nervous System Neoplasms / radiography. Rhabdoid Tumor / pathology. Rhabdoid Tumor / radiography. Teratoma / pathology. Teratoma / radiography
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Prognosis. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15841745.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


52. Jahnke K, Thiel E, Schilling A, Herrlinger U, Weller M, Coupland SE, Krümpelmann U, Stein H, Korfel A: Low-grade primary central nervous system lymphoma in immunocompetent patients. Br J Haematol; 2005 Mar;128(5):616-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade primary central nervous system lymphoma in immunocompetent patients.
  • Primary central nervous system lymphomas (PCNSL) are usually diffuse large B-cell non-Hodgkin's lymphomas (NHL).
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / therapy. Magnetic Resonance Imaging. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15725082.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


53. Evens AM, Ziegler SL, Gupta R, Augustyniak C, Gordon LI, Mehta J: Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma. Clin Lymphoma Myeloma; 2007 Jul;7(7):472-4
Hazardous Substances Data Bank. ZIDOVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma.
  • Human T-lymphotrophic virus-1-associated adult T-cell leukemia/lymphoma (ATLL) is a rare and often fatal disease.
  • This study reports on a 55-year-old man with relapsed/refractory leukemic-phase ATLL including significant central nervous system (CNS) disease with resistance to previous zidovudine/IFN and arsenic trioxide/IFN treatment.
  • The patient experienced a rapid hematologic and CNS clinical response with single-agent denileukin diftitox therapy (18 microg/kg per day for 5 days).
  • He tolerated 8 cycles of denileukin diftitox therapy well and experienced a sustained complete hematologic and CNS remission.
  • [MeSH-major] Bone Marrow Transplantation. Central Nervous System Neoplasms / therapy. Diphtheria Toxin / administration & dosage. Hematologic Neoplasms / therapy. Interleukin-2 / administration & dosage. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Arsenicals / administration & dosage. Drug Resistance, Neoplasm / drug effects. Humans. Interferons / administration & dosage. Male. Middle Aged. Oxides / administration & dosage. Recombinant Fusion Proteins / administration & dosage. Recurrence. Remission Induction. Transplantation, Homologous. Zidovudine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875237.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Oxides; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox; 4B9XT59T7S / Zidovudine; 9008-11-1 / Interferons; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


54. Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y: Secondary central nervous system lymphoma. Int J Hematol; 2006 Aug;84(2):128-35
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary central nervous system lymphoma.
  • This review summarizes current knowledge of secondary central nervous system lymphoma (SCNSL) in adults.
  • We define SCNSL as CNS involvement not obvious at the initiation of treatment for systemic lymphoma.
  • We reviewed reports of patients treated without CNS prophylaxis to evaluate the incidence of SCNSL.
  • Prevention of isolated CNS recurrence is thought to be the main target of CNS prophylaxis.
  • The value of CNS prophylaxis according to histologic subtype, status of systemic lymphoma, and other risk factors is summarized.
  • CNS involvement is almost always fatal; however, a CNS-active strategy could complement other approaches that have led to recent improvements in the prognosis for lymphoma.
  • [MeSH-major] Central Nervous System Neoplasms. Lymphoma
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antimetabolites, Antineoplastic / administration & dosage. Cytarabine / administration & dosage. Female. Humans. Male. Recurrence. Rituximab. Stem Cell Transplantation / mortality

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16926134.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 75
  •  go-up   go-down


55. Combs SE, Thilmann C, Debus J, Schulz-Ertner D: Precision radiotherapy for hemangiopericytomas of the central nervous system. Cancer; 2005 Dec 1;104(11):2457-65
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precision radiotherapy for hemangiopericytomas of the central nervous system.
  • The present analysis evaluates the role of precision RT in the management of HAP of the central nervous system (CNS) and represents one of the largest series of HAP treated with RT that can be found in the literature.
  • METHODS: Of 37 consecutive patients with histologically confirmed HAP who were treated at the institution between 1984 and 2004, the majority, 25 tumors, was localized within the skull base (n = 25) and 4 tumors were localized at the spine.
  • CONCLUSION: High-precision RT is an effective and safe treatment modality for patients with HAP of the CNS and the spine and achieves highly acceptable tumor control, while sparing normal tissue.
  • [MeSH-major] Central Nervous System Neoplasms / radiotherapy. Hemangiopericytoma / radiotherapy. Radiotherapy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Disease-Free Survival. Dose Fractionation. Follow-Up Studies. Humans. Middle Aged. Retrospective Studies. Stereotaxic Techniques. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16222690.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Haldorsen IS, Espeland A, Larsen JL, Mella O: Diagnostic delay in primary central nervous system lymphoma. Acta Oncol; 2005;44(7):728-34
Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic delay in primary central nervous system lymphoma.
  • This study investigates delay in diagnosing primary central nervous system lymphoma (PCNSL), which has a variable clinical and radiological presentation.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neurologic Examination. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227164.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


57. Fischer L, Korfel A, Pfeiffer S, Kiewe P, Volk HD, Cakiroglu H, Widmann T, Thiel E: CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res; 2009 Oct 1;15(19):5968-73
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXCL13 and CXCL12 in central nervous system lymphoma patients.
  • PURPOSE: Homing of malignant lymphocytes to the central nervous system (CNS) may play a role in the pathogenesis of CNS lymphoma.
  • In this study, we evaluated the chemokines CXCL12 and CXCL13 in the cerebrospinal fluid (CSF) and serum of patients with CNS lymphoma.
  • EXPERIMENTAL DESIGN: Samples from 30 patients with CNS lymphoma (23 with primary and 7 with secondary CNS lymphoma; all B-cell lymphoma) and 40 controls (10 patients with other CNS malignancies and 30 without a malignant CNS disease) were examined.
  • RESULTS: CNS lymphoma patients and controls did not differ in CXCL12 serum and CSF levels.
  • CXCL13 CSF levels, however, were significantly higher in CNS lymphoma patients as compared with controls (P < 0.0001).
  • In CNS lymphoma, CXCL13 concentration in CSF correlated with the degree of blood-brain barrier disruption (R = 0.66; P = 0.003).
  • Elevated CSF levels of CXCL12 and CXCL13 measured in seven CNS lymphoma patients during therapy decreased in five patients who responded to chemotherapy and increased in two with lymphoma progression.
  • CONCLUSIONS: Our results suggest a production of CXCL13 within the CNS of CNS lymphoma patients, which decreases with response to therapy.
  • [MeSH-major] Central Nervous System Neoplasms / blood. Central Nervous System Neoplasms / cerebrospinal fluid. Chemokine CXCL12. Chemokine CXCL13. Lymphoma / blood. Lymphoma / cerebrospinal fluid
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Biomarkers, Tumor / cerebrospinal fluid. Case-Control Studies. Disease Progression. Female. Humans. Ifosfamide / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19773382.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCL13 protein, human; 0 / Chemokine CXCL12; 0 / Chemokine CXCL13; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


58. Lee VH, Connolly HM, Brown RD Jr: Central nervous system manifestations of cardiac myxoma. Arch Neurol; 2007 Aug;64(8):1115-20
MedlinePlus Health Information. consumer health - Brain Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system manifestations of cardiac myxoma.
  • Potential delayed neurologic complications relevant to patients with tumor embolization include myxoma-induced cerebral aneurysm and myxomatous metastasis, which can mimic the clinical picture of central nervous system vasculitis or infective endocarditis.
  • [MeSH-major] Brain Diseases / etiology. Heart Neoplasms / complications. Myxoma / complications
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / pathology. Brain / radiography. Echocardiography, Transesophageal. Female. Heart Atria. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17698701.001).
  • [ISSN] 0003-9942
  • [Journal-full-title] Archives of neurology
  • [ISO-abbreviation] Arch. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Fuller CE, Perry A: Molecular diagnostics in central nervous system tumors. Adv Anat Pathol; 2005 Jul;12(4):180-94
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnostics in central nervous system tumors.
  • Central nervous system (CNS) neoplasms can be diagnostically challenging, due to remarkably wide ranges in histologic appearance, biologic behavior, and therapeutic approach.
  • In this regard, the field is primed by recent advances in basic research, elucidating the molecular mechanisms of tumorigenesis and progression in the most common adult and pediatric brain tumors.
  • Thus far, few have made the transition into routine clinical practice, the most notable example being 1p and 19q testing in oligodendroglial tumors.
  • The goal of this article is to highlight the most common genetic alterations currently implicated in CNS tumors, focusing most on those that are either already in common use in ancillary molecular diagnostics testing or are likely to become so in the near future.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Central Nervous System Neoplasms / genetics. Ependymoma / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Animals. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Chromosome Aberrations. Humans. In Situ Hybridization, Fluorescence. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / genetics. Meningioma / diagnosis. Meningioma / genetics. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / genetics. Polymerase Chain Reaction. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096380.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 260
  •  go-up   go-down


60. Kiewe P, Fischer L, Martus P, Thiel E, Korfel A: Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis. Cancer; 2008 Apr 15;112(8):1812-20
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.
  • BACKGROUND: This retrospective, single-center study assessed the feasibility, outcome, and late side effects of the treatment of immunocompetent patients with primary central nervous system lymphoma (PCNSL) at the authors' institution.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Central Nervous System Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Methotrexate / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cranial Irradiation. Disease Progression. Disease-Free Survival. Feasibility Studies. Female. Follow-Up Studies. Humans. Karnofsky Performance Status. Longitudinal Studies. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18318432.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


61. Lassman AB, Abrey LE, Shah GD, Panageas KS, Begemann M, Malkin MG, Raizer JJ: Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol; 2006 Jul;78(3):255-60
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic high-dose intravenous methotrexate for central nervous system metastases.
  • BACKGROUND: Treatment options for patients with recurrent central nervous system (CNS) metastases are limited.
  • METHODS: Medical records were reviewed for all patients treated with HD IV MTX (3.5 g/m2) for CNS parenchymal or leptomeningeal metastases.
  • CONCLUSIONS: HD IV MTX is effective in the treatment of CNS metastases with disease control (response or stable) as a best response in 56% of assessable patients.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / secondary. Methotrexate / administration & dosage
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / drug therapy. Breast Neoplasms / mortality. Breast Neoplasms / pathology. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Dose-Response Relationship, Drug. Female. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / pathology. Humans. Infusions, Intravenous. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Lung Neoplasms / pathology. Male. Middle Aged. Neoplasms, Unknown Primary / drug therapy. Neoplasms, Unknown Primary / mortality. Neoplasms, Unknown Primary / pathology. Retrospective Studies. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Neurooncol. 2006 Jul;78(3):261. Shah, Gaurav G [corrected to Shah, Gaurav D]
  • (PMID = 16344918.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA009512
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


62. Warnke PC, Timmer J, Ostertag CB, Kopitzki K: Capillary physiology and drug delivery in central nervous system lymphomas. Ann Neurol; 2005 Jan;57(1):136-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capillary physiology and drug delivery in central nervous system lymphomas.
  • To evaluate whether the chemosensitivity of primary central nervous system lymphomas to water-soluble drugs could result from improved drug delivery, we quantitatively assessed pharmacokinetic factors in seven patients.
  • The capillary permeability surface product was found to be significantly increased in central nervous system lymphomas compared with glioblastoma multiforme, medulloblastomas, and metastases.
  • Our results suggest favorable pharmacokinetics to water- and lipid-soluble drugs in primary central nervous system lymphomas.
  • [MeSH-major] Capillaries / physiopathology. Central Nervous System Neoplasms / physiopathology. Lymphoma / physiopathology. Regional Blood Flow / physiology
  • [MeSH-minor] Adult. Aged. Brain Mapping. Contrast Media / administration & dosage. Drug Delivery Systems. Female. Humans. Image Processing, Computer-Assisted / methods. Iopamidol / administration & dosage. Male. Middle Aged. Models, Theoretical. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15622544.001).
  • [ISSN] 0364-5134
  • [Journal-full-title] Annals of neurology
  • [ISO-abbreviation] Ann. Neurol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; JR13W81H44 / Iopamidol
  •  go-up   go-down


63. Küsters-Vandevelde HV, Klaasen A, Küsters B, Groenen PJ, van Engen-van Grunsven IA, van Dijk MR, Reifenberger G, Wesseling P, Blokx WA: Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol; 2010 Mar;119(3):317-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system.
  • Primary melanocytic neoplasms of the central nervous system (CNS) are uncommon neoplasms derived from melanocytes that normally can be found in the leptomeninges.
  • Characteristic genetic alterations in this group of neoplasms have not yet been identified.
  • Using direct sequencing, we investigated 19 primary melanocytic lesions of the CNS (12 melanocytomas, 3 intermediate-grade melanocytomas, and 4 melanomas) for hotspot oncogenic mutations commonly found in melanocytic tumors of the skin (BRAF, NRAS, and HRAS genes) and uvea (GNAQ gene).
  • Somatic mutations in the GNAQ gene at codon 209, resulting in constitutive activation of GNAQ, were detected in 7/19 (37%) tumors, including 6/12 melanocytomas, 0/3 intermediate-grade melanocytomas, and 1/4 melanomas.
  • These GNAQ-mutated tumors were predominantly located around the spinal cord (6/7).
  • One melanoma carried a BRAF point mutation that is frequently found in cutaneous melanomas (c.1799 T>A, p.V600E), raising the question whether this is a metastatic rather than a primary tumor.
  • We conclude that somatic mutations in the GNAQ gene at codon 209 are a frequent event in primary melanocytic neoplasms of the CNS.
  • This finding provides new insight in the pathogenesis of these lesions and suggests that GNAQ-dependent mitogen-activated kinase signaling is a promising therapeutic target in these tumors.
  • The prognostic and predictive value of GNAQ mutations in primary melanocytic lesions of the CNS needs to be determined in future studies.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Central Nervous System Neoplasms / pathology. GTP-Binding Protein alpha Subunits / genetics. Melanocytes / pathology. Melanoma / pathology. Mutation / genetics
  • [MeSH-minor] Adult. Aged. Codon / genetics. DNA, Neoplasm / genetics. DNA, Neoplasm / isolation & purification. Female. Genes, ras / genetics. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Proto-Oncogene Proteins B-raf / genetics. Retrospective Studies. Tissue Fixation

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2290-1 [19349541.001]
  • [Cites] Br J Cancer. 2009 Sep 1;101(5):813-5 [19654573.001]
  • [Cites] PLoS One. 2009;4(8):e6833 [19718445.001]
  • [Cites] Nature. 1999 Dec 2;402(6761):496-501 [10591209.001]
  • [Cites] Annu Rev Biochem. 2000;69:795-827 [10966476.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3468-74 [12429636.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5761-6 [14522897.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] J Invest Dermatol. 2003 Nov;121(5):1160-2 [14708620.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):705-10 [15252839.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):961-8 [15322542.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):935-6 [15340429.001]
  • [Cites] Neurosurgery. 1981 Jan;8(1):26-30 [7207769.001]
  • [Cites] J Invest Dermatol. 1984 Mar;82(3):235-8 [6699426.001]
  • [Cites] J Neurosurg. 1987 Jun;66(6):948 [3572529.001]
  • [Cites] Annu Rev Biochem. 1987;56:779-827 [3304147.001]
  • [Cites] Cancer. 1988 May 1;61(9):1926-34 [3355984.001]
  • [Cites] J Am Acad Dermatol. 1991 May;24(5 Pt 1):747-55 [1869648.001]
  • [Cites] Neurology. 1993 Feb;43(2):381-6 [8437707.001]
  • [Cites] Science. 1993 Dec 17;262(5141):1895-901 [8266082.001]
  • [Cites] Neurosurgery. 1994 Mar;34(3):533-7; discussion 637 [8190231.001]
  • [Cites] Pathologica. 1997 Apr;89(2):168-74 [9411364.001]
  • [Cites] Am J Surg Pathol. 1999 Jul;23(7):745-54 [10403296.001]
  • [Cites] Acta Neurochir (Wien). 2005 Mar;147(3):313-5; discussion 315 [15618991.001]
  • [Cites] Melanoma Res. 2006 Apr;16(2):97-103 [16567964.001]
  • [Cites] Melanoma Res. 2006 Aug;16(4):267-73 [16845322.001]
  • [Cites] Cell Oncol. 2007;29(1):19-24 [17429138.001]
  • [Cites] Hum Mutat. 2007 Jun;28(6):578-88 [17295241.001]
  • [Cites] Curr Opin Oncol. 2008 Mar;20(2):183-9 [18300768.001]
  • [Cites] J Neurosurg Spine. 2008 Jul;9(1):48-54 [18590410.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5230-4 [18719078.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):599-602 [19078957.001]
  • (PMID = 19936769.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Codon; 0 / DNA, Neoplasm; 0 / GNAQ protein, human; 0 / GTP-Binding Protein alpha Subunits; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


64. Neglia JP, Robison LL, Stovall M, Liu Y, Packer RJ, Hammond S, Yasui Y, Kasper CE, Mertens AC, Donaldson SS, Meadows AT, Inskip PD: New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst; 2006 Nov 1;98(21):1528-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.
  • BACKGROUND: Subsequent primary neoplasms of the central nervous system (CNS) have frequently been described as late events following childhood leukemia and brain tumors.
  • METHODS: Subsequent primary neoplasms of the CNS occurring within a cohort of 14,361 5-year survivors of childhood cancers were ascertained.
  • Tumor site-specific radiation dosimetry was performed, and chemotherapy information was abstracted from medical records.
  • RESULTS: Subsequent CNS primary neoplasms were identified in 116 individuals.
  • CONCLUSIONS: Exposure to radiation therapy is the most important risk factor for the development of a new CNS tumor in survivors of childhood cancers.
  • [MeSH-major] Brain / drug effects. Brain Neoplasms / epidemiology. Neoplasms, Second Primary / epidemiology. Survivors / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Age Factors. Canada / epidemiology. Case-Control Studies. Central Nervous System Neoplasms / epidemiology. Child. Child, Preschool. Dose-Response Relationship, Radiation. Female. Glioma / epidemiology. Humans. Incidence. Logistic Models. Male. Meningioma / epidemiology. Neoplasms / therapy. Odds Ratio. Radiometry. Radiotherapy / adverse effects. Retrospective Studies. Risk Assessment. Risk Factors. United States / epidemiology

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2006 Nov 1;98(21):1510-1 [17077348.001]
  • (PMID = 17077355.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / PHS HHS / / U24 55727; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


65. Armstrong GT, Liu Q, Yasui Y, Huang S, Ness KK, Leisenring W, Hudson MM, Donaldson SS, King AA, Stovall M, Krull KR, Robison LL, Packer RJ: Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst; 2009 Jul 1;101(13):946-58
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study.
  • BACKGROUND: Adult survivors of childhood central nervous system (CNS) malignancies are at high risk for long-term morbidity and late mortality.
  • However, patterns of late mortality, the long-term risks of subsequent neoplasms and debilitating medical conditions, and sociodemographic outcomes have not been comprehensively characterized for individual diagnostic and treatment groups.
  • METHODS: We collected information on treatment, mortality, chronic medical conditions, and neurocognitive functioning of adult 5-year survivors of CNS malignancies diagnosed between 1970 and 1986 within the Childhood Cancer Survivor Study.
  • Using competing risk framework, we calculated cumulative mortality according to cause of death and cumulative incidence of subsequent neoplasms according to exposure and dose of cranial radiation therapy (RT).
  • Neurocognitive impairment and socioeconomic outcomes were assessed with respect to dose of CNS radiotherapy to specific brain regions.
  • Patients who received cranial RT of 50 Gy or more (n = 813) had a cumulative incidence of a subsequent neoplasm within the CNS of 7.1% (95% CI = 4.5% to 9.6%) at 25 years from diagnosis compared with 1.0% (95% CI = 0% to 2.3%) for patients who had no RT.
  • Neurocognitive impairment was high and proportional to radiation dose for specific tumor types.
  • CONCLUSIONS: Survivors of childhood CNS malignancies are at high risk for late mortality and for developing subsequent neoplasms and chronic medical conditions.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 1994 Jul 16;309(6948):162-6 [8044095.001]
  • [Cites] J Natl Cancer Inst. 2008 Oct 1;100(19):1368-79 [18812549.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] J Neurol. 2002 Aug;249(8):955-60 [12195437.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):663-73 [12548609.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1115-26 [12569614.001]
  • [Cites] J Neurooncol. 2003 Jul;63(3):279-87 [12892234.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3255-61 [12947060.001]
  • [Cites] JAMA. 2003 Sep 24;290(12):1583-92 [14506117.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4731-9 [14557448.001]
  • [Cites] Pediatr Hematol Oncol. 2003 Dec;20(8):617-25 [14578032.001]
  • [Cites] Neuropsychology. 2003 Oct;17(4):548-55 [14599268.001]
  • [Cites] Curr Opin Neurol. 2003 Dec;16(6):677-83 [14624076.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):999-1006 [15020603.001]
  • [Cites] Ann Fam Med. 2004 Jan-Feb;2(1):61-70 [15053285.001]
  • [Cites] Cancer. 2004 May 15;100(10):2246-52 [15139071.001]
  • [Cites] J Clin Epidemiol. 2004 Sep;57(9):933-44 [15504636.001]
  • [Cites] Am J Epidemiol. 1986 Jan;123(1):174-84 [3509965.001]
  • [Cites] Am J Clin Oncol. 1985 Dec;8(6):472-6 [3936349.001]
  • [Cites] Arch Dis Child. 1990 Dec;65(12):1356-63 [2270944.001]
  • [Cites] J Clin Oncol. 1991 Apr;9(4):592-9 [2066756.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1397-406 [1517782.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2188-97 [18792068.001]
  • [Cites] Int J Epidemiol. 1998 Feb;27(1):91-5 [9563700.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1723-8 [9586884.001]
  • [Cites] Ann Neurol. 1998 Sep;44(3):313-6 [9749596.001]
  • [Cites] Med Pediatr Oncol. 1998 Dec;31(6):506-11 [9835903.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] J Neurooncol. 1999 Jan;41(1):47-53 [10222422.001]
  • [Cites] Br J Cancer. 2004 Nov 29;91(11):1905-10 [15534607.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4979-90 [15576413.001]
  • [Cites] Pediatr Blood Cancer. 2005 Aug;45(2):155-61 [15880357.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):637-44 [16421901.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jul;47(1):83-8 [16317732.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2536-43 [16735706.001]
  • [Cites] Radiat Res. 2006 Jul;166(1 Pt 2):141-57 [16808603.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1084-91 [16870549.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Eur J Cancer. 2007 Jan;43(2):351-62 [17141498.001]
  • [Cites] Pediatr Blood Cancer. 2007 Apr;48(4):460-7 [16767717.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1532-8 [17442996.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jul;49(1):47-51 [16755550.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4014-21 [18258798.001]
  • [Cites] Cancer. 2008 May 1;112(9):2071-9 [18327823.001]
  • [Cites] Pediatr Blood Cancer. 2008 Aug;51(2):245-50 [18386785.001]
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4401-9 [18802152.001]
  • [CommentIn] J Natl Cancer Inst. 2009 Jul 1;101(13):908-10 [19549957.001]
  • [CommentIn] J Natl Cancer Inst. 2009 Jul 1;101(13):909 [19549959.001]
  • (PMID = 19535780.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24-CA55727
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2704230
  •  go-up   go-down


66. Batoroev IuK: [Cytomorphological diagnosis in the primary central nervous system lymphoma]. Klin Lab Diagn; 2010 Jan;(1):32-5
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytomorphological diagnosis in the primary central nervous system lymphoma].
  • The paper provides a retrospective analysis of cases of the cytological diagnosis of the rare abnormality--primary central nervous system (CNS) lymphomas.
  • The capabilities, advantages, and disadvantages of diagnosis of both cytological and histological diagnosis of CNS lymphomas are estimated.
  • [MeSH-major] Brain Neoplasms / diagnosis. Lymphoma / diagnosis. Spinal Cord Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20201375.001).
  • [ISSN] 0869-2084
  • [Journal-full-title] Klinicheskaia laboratornaia diagnostika
  • [ISO-abbreviation] Klin. Lab. Diagn.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


67. Shukla K, Parikh B, Shukla J, Trivedi P, Shah B: Accuracy of cytologic diagnosis of central nervous system tumours in crush preparation. Indian J Pathol Microbiol; 2006 Oct;49(4):483-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of cytologic diagnosis of central nervous system tumours in crush preparation.
  • The aim of this study was to assess the usefulness and accuracy of cytologic smears by making crush preparation as a diagnostic method, in central nervous system tumors.
  • 278 patients with central nervous system tumors were investigated.
  • The most common tumor in intracranial cavity was astrocytoma (56.68%), followed by meningioma (6.88%), medulloblastoma (5.66%) and ependymoma (5.56%).
  • The most common tumor in intraspinal cavity was ependymoma (38.46%), followed by meningioma (23.07%) and schwannoma (23.07%).
  • In conclusion, crush preparation is an effective, simple, rapid, relatively safe and reliable technique for the diagnosis of central nervous system tumors.
  • [MeSH-major] Astrocytoma. Central Nervous System Neoplasms / diagnosis. Cytodiagnosis. Ependymoma. Medulloblastoma. Meningioma. Neurilemmoma
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cytological Techniques / methods. Female. Humans. Male. Middle Aged. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17183833.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] India
  •  go-up   go-down


68. Paul T, Challa S, Tandon A, Panigrahi M, Purohit A: Primary central nervous system lymphomas: Indian experience, and review of literature. Indian J Cancer; 2008 Jul-Sep;45(3):112-8
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphomas: Indian experience, and review of literature.
  • Primary central nervous system lymphomas (PCNSLs) are a rare form of non-Hodgkin's lymphoma which arise within and remain confined primarily to the central nervous system (CNS).
  • They generally account for 1-2% of all primary brain tumors and are reported to be on the rise due to the Acquired Immune Deficiency Syndrome (AIDS) epidemic.
  • RESULTS: In a 19-year study period, there were 56 patients of PCNSLs, accounting for 1.07% of all intracranial neoplasms.
  • [MeSH-major] Brain Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD20 / metabolism. Antigens, CD3 / metabolism. Antigens, CD45 / metabolism. Child. Female. Humans. Immunocompetence. Immunoenzyme Techniques. India / epidemiology. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018115.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


69. Pilkington GJ: Cancer stem cells in the mammalian central nervous system. Cell Prolif; 2005 Dec;38(6):423-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer stem cells in the mammalian central nervous system.
  • Malignant tumours intrinsic to the central nervous system (CNS) are among the most difficult of neoplasms to treat effectively.
  • The major biological features of these tumours that preclude successful therapy include their cellular heterogeneity, which renders them highly resistant to both chemotherapy and radiotherapy, and the propensity of the component tumour cells to invade, diffusely, the contiguous nervous tissues.
  • In the 1970s transplacental administration of the potent neurocarcinogen, N-ethyl-N-nitrosourea (ENU), enabled investigation of the sequential development of brain and spinal neoplasms by electron microscopy and immunohistochemistry.
  • Since then, the development of new cell culture methods, including the in vitro growth of neurospheres and multicellular tumour spheroids, and new antigenic markers of stem cells and glial/neuronal cell precursor cells, including nestin, Mushashi-1 and CD133, have led to a reappraisal of the histological classification and origins of CNS tumours.
  • Interestingly, while the stem cell marker CD133 is expressed in these primitive neuroectodermal tumours (PNETs), the chondroitin sulphate proteoglycan neuronal/glial 2 (NG2), which appears to denote increased proliferative, but reduced migratory activity in adult gliomas, is rarely expressed.
  • The divergent pathways of differentiation of CNS tumours and the possibility of stem cell origin, for some, if not all, such neoplasms remain a matter for debate and continued research, but the presence of self-renewing neural stem cells in the CNS of both children and adults strongly suggests a role for these cells in tumour initiation and resistance to current therapeutic strategies.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Neoplastic Stem Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16300654.001).
  • [ISSN] 0960-7722
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 62
  •  go-up   go-down


70. Alameda F, Lloreta J, Ariza A, Salido M, Espinet B, Baro T, Garcia-Fructoso G, Galito E, Munne A, Cruz Sanchez FF, Sole F, Serrano S: Primitive neuroectodermal tumor of the central nervous system with glial differentiation: a FISH study of an adult case. Clin Neuropathol; 2007 Jan-Feb;26(1):12-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive neuroectodermal tumor of the central nervous system with glial differentiation: a FISH study of an adult case.
  • Primitive neuroectodermal tumors (PNETs) of the central nervous system (CNS), a rare occurrence in adults, may show glial differentiation and can be misinterpreted as pure astrocytic neoplasms.
  • Few fluorescence in situ hybridization (FISH) studies have been carried out on these tumors; isochromosome 17q was found to be the major chromosomal abnormality.
  • We present the case of an adult in which we performed a FISH study of both the glial and neuronal components.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Chromosomes, Human, Pair 17 / genetics. Neuroectodermal Tumors, Primitive / genetics. Neuroectodermal Tumors, Primitive / pathology. Trisomy / genetics
  • [MeSH-minor] Adult. Humans. In Situ Hybridization, Fluorescence. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290931.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


71. Kamoshima Y, Sawamura Y: Update on current standard treatments in central nervous system germ cell tumors. Curr Opin Neurol; 2010 Dec;23(6):571-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on current standard treatments in central nervous system germ cell tumors.
  • PURPOSE OF REVIEW: Various approaches have been used for the management of patients with germ cell tumors (GCTs) in the central nervous system (CNS); however, the optimal treatment of both germinoma and nongerminomatous GCTs remains unknown.
  • This review discusses current management strategies and late effects of therapy for CNS GCTs.
  • SUMMARY: The 10-year survival rate of CNS germinoma is approximately 90%.
  • Most patients with CNS GCTs are children and young adults.
  • Therefore, with the improving life prognosis of young patients, secondary neoplasms, secondary cerebral vasculopathy, neurocognitive deficits, and many other adverse effects induced by the initial treatments are problems to be solved in the next decade.
  • [MeSH-major] Antineoplastic Protocols / standards. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / radiotherapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Antineoplastic Combined Chemotherapy Protocols / standards. Child. Germinoma / drug therapy. Germinoma / mortality. Germinoma / radiotherapy. Humans. Survival Rate / trends. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20885323.001).
  • [ISSN] 1473-6551
  • [Journal-full-title] Current opinion in neurology
  • [ISO-abbreviation] Curr. Opin. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


72. Kułakowska A, Pogorzelski R, Drozdowski W: [Primary central nervous system lymphoma with initial symptoms suggesting herpes encephalitis]. Pol Merkur Lekarski; 2008 Jan;24(139):30-3
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary central nervous system lymphoma with initial symptoms suggesting herpes encephalitis].
  • Primary central nervous system lymphoma (PCNSL) is rare neoplasm, affecting both immunocompetent and immunodeficient patients.
  • It is usually seen as intracranial tumor, but it can often involve cerebrospinal meninges, eyeballs and spinal cord.
  • We described a case of 43 year old patient with diagnosed PCNSL and discussed clinical signs, diagnostics and treatment of the neoplasm.
  • [MeSH-major] Brain Neoplasms / diagnosis. Encephalitis, Herpes Simplex / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Diagnosis, Differential. Fatal Outcome. Humans. Male

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18634249.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


73. Zhang N, Liu ZJ, Li G, Xiao B, Liu YH, Li GL, Lu BQ, Liang JH: [Clinical and pathologic features of melanocytic lesion of the central nervous system]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Aug;32(4):713-7
MedlinePlus Health Information. consumer health - Neurologic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and pathologic features of melanocytic lesion of the central nervous system].
  • OBJECTIVE: To investigate the clinical and pathologic features of melanocytic lesion of the central nervous system.
  • CONCLUSION: Intracranial hypertension and epilepsy are the main clinical manifestations of melanocytic lesion of the central nervous system, and cutaneous lesion and radiological findings are very important for the diagnosis.
  • [MeSH-major] Melanosis / pathology. Nervous System Diseases / pathology. Neurocutaneous Syndromes / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Meningeal Neoplasms / pathology. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17767073.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] Neurocutaneous melanosis
  •  go-up   go-down


74. Juergens A, Pels H, Rogowski S, Fliessbach K, Glasmacher A, Engert A, Reiser M, Diehl V, Vogt-Schaden M, Egerer G, Schackert G, Reichmann H, Kroschinsky F, Bode U, Herrlinger U, Linnebank M, Deckert M, Fimmers R, Schmidt-Wolf IG, Schlegel U: Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol; 2010 Feb;67(2):182-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma.
  • OBJECTIVE: To evaluate long-term progression-free survival and overall survival, quality of life, and cognitive function in primary central nervous system lymphoma after systemic and intraventricular chemotherapy without radiotherapy.
  • METHODS: A long-term follow-up was conducted on surviving primary central nervous system lymphoma patients having been enrolled in a pilot/phase II trial between September 1995 and December 2001.
  • INTERPRETATION: Primary polychemotherapy based on high-dose methotrexate (MTX) and cytarabine (Ara-C) is highly efficient in treatment of primary central nervous system lymphoma.
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / mortality. Cognition Disorders / chemically induced. Drug-Related Side Effects and Adverse Reactions. Lymphoma / drug therapy. Lymphoma / mortality
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Humans. Longitudinal Studies. Middle Aged. Neuropsychological Tests. Quality of Life. Reaction Time / physiology. Retrospective Studies. Treatment Outcome


75. Iqbal M, Shah A, Wani MA, Kirmani A, Ramzan A: Cytopathology of the central nervous system. Part I. Utility of crush smear cytology in intraoperative diagnosis of central nervous system lesions. Acta Cytol; 2006 Nov-Dec;50(6):608-16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytopathology of the central nervous system. Part I. Utility of crush smear cytology in intraoperative diagnosis of central nervous system lesions.
  • OBJECTIVE: To evaluate the utility of rapid intraoperative crush smear cytologic diagnosis of central and peripheral nervous system lesions and to determine the accuracy and relevance of the accuracy of the intraoperative cytologic diagnosis when compared to the final paraffin section diagnosis.
  • CONCLUSION: In the expert hands of a pathologist with good exposure neurosurgical specimens, crush smear cytology is an accura and reliable procedure for the intraoperative diagnosis central nervous system tumors.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Histological Techniques / methods. Peripheral Nervous System Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy / methods. Biopsy / standards. Child. Child, Preschool. Female. Humans. Infant. Intraoperative Period. Male. Middle Aged. Paraffin Embedding. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152270.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Okita R, Saeki T, Takashima S, Aogi K, Ohsumi S: Progressive central nervous system metastases in responder patients for outside central nervous system metastases on trastuzumab-based therapy--report of two cases of refractory breast cancer. Hiroshima J Med Sci; 2005 Mar;54(1):35-8
Hazardous Substances Data Bank. Trastuzumab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive central nervous system metastases in responder patients for outside central nervous system metastases on trastuzumab-based therapy--report of two cases of refractory breast cancer.
  • We report two cases of central nervous system (CNS) metastases during systemic response to trastuzumab in combination with chemotherapy for refractory breast cancer.
  • A follow-up computed tomography scan revealed that their diseases continued to respond outside the CNS.
  • These cases suggest that the failure of trastuzumab to cross the blood-brain barrier may compromise its overall effectiveness and raises the possibility that CNS metastasis may become clinically more significant in patients receiving antibody-based therapies, including patients responding to therapy outside the CNS.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Breast Neoplasms / therapy. Cerebellar Neoplasms / secondary
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Blood-Brain Barrier. Combined Modality Therapy. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Radiosurgery. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15847063.001).
  • [ISSN] 0018-2052
  • [Journal-full-title] Hiroshima journal of medical sciences
  • [ISO-abbreviation] Hiroshima J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; P188ANX8CK / Trastuzumab
  •  go-up   go-down


77. Jabbour E, Thomas D, Cortes J, Kantarjian HM, O'Brien S: Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer; 2010 May 15;116(10):2290-300
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies.
  • Central nervous system (CNS) recurrence continues to be a significant complication in the treatment of adult patients with acute lymphoblastic leukemia (ALL).
  • Preventing CNS recurrence has been a therapeutic challenge and has not been addressed critically in many clinical trials.
  • Adult studies modeled on childhood ALL studies have used multiple treatment modalities, including radiation therapy, systemic therapy, intrathecal therapy, and combinations thereof.
  • Systemic chemotherapy, especially with cytarabine (AraC) and methotrexate, has demonstrated promise in decreasing CNS recurrence, but therapeutic levels of drugs in the cerebrospinal fluid (CSF) are not maintained.
  • Intrathecal chemotherapy with or without high-dose systemic therapy is the most common approach to CNS prophylaxis.
  • Liposomal AraC recently has become available and confers prolonged levels of free AraC in the CSF, a critical requirement for CNS prophylactic therapy.
  • This review discusses the various modalities used for CNS prophylaxis in patients with ALL and the emerging trends, with specific emphasis on the outcome in terms of event-free survival and toxicity.
  • [MeSH-major] Central Nervous System / pathology. Leukemic Infiltration / prevention & control. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cranial Irradiation. Humans. Injections, Spinal. Meningeal Carcinomatosis / prevention & control. Meningeal Neoplasms / prevention & control. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Cancer Society.
  • (PMID = 20209620.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 92
  •  go-up   go-down


78. Dubik-Jezierzańska M, Pokryszko-Dragan A, Turek T, Budrewicz S, Pawlik B: [Diagnostic problems in case of primary central nervous system lymphoma]. Wiad Lek; 2006;59(7-8):552-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic problems in case of primary central nervous system lymphoma].
  • The authors described a case of young patient with primary central nervous system lymphoma (PCNSL).
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / surgery
  • [MeSH-minor] Adult. Biopsy / methods. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Methotrexate / therapeutic use. Neoplasm Recurrence, Local / diagnosis. Radiotherapy. Stereotaxic Techniques. Treatment Outcome

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17209358.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


79. Erickson ML, Johnson R, Bannykh SI, de Lotbiniere A, Kim JH: Malignant rhabdoid tumor in a pregnant adult female: literature review of central nervous system rhabdoid tumors. J Neurooncol; 2005 Sep;74(3):311-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant rhabdoid tumor in a pregnant adult female: literature review of central nervous system rhabdoid tumors.
  • Rhabdoid tumors of the central nervous system are uncommon, aggressive childhood malignancies.
  • The 13 described adult cases comprise both primary CNS tumors and malignant transformation of previously existing gliomas, meningiomas, and astrocytomas.
  • Central nervous system rhabdoid lesions of adults have been diagnosed as primary malignant rhabdoid tumors, atypical teratoid/rhabdoid tumors, and more recently, rhabdoid glioblastomas.
  • Pathologic evaluation revealed histology, electron microscopy and immunohistochemistry consistent with the diagnosis of malignant rhabdoid tumor.
  • FISH studies were negative for the INI-1 genetic mutations and chromosome 22q deletion associated with childhood atypical rhabdoid/rhabdoid tumor in 75% of cases.
  • We briefly describe the characteristics and current understanding of rhabdoid tumors, and review the literature comparing the 12 other cases of central nervous system rhabdoid tumors in adults.
  • Furthermore, we consider and discuss the implications of this case being the second presentation of MRT during pregnancy in only six adult female patients.
  • [MeSH-major] Brain Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology. Rhabdoid Tumor / pathology
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Microscopy, Electron, Transmission. Pregnancy


80. Wang Z, Fan QH, Yu MN, Zhang WM: [Clinicopathologic and immunohistochemical study of atypical teratoid/rhabdoid tumor of central nervous system]. Zhonghua Bing Li Xue Za Zhi; 2006 Aug;35(8):458-61
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic and immunohistochemical study of atypical teratoid/rhabdoid tumor of central nervous system].
  • OBJECTIVE: To study the clinicopathologic features and differential diagnosis of atypical teratoid/rhabdoid tumor (AT/RT) occurring in the central nervous system.
  • The tumor cells were positive for vimentin, CD99, epithelial membrane antigen, cytokeratin, glial fibrillary acidic protein, S-100 protein, neurofilament, desmin and smooth muscle actin.
  • CONCLUSIONS: AT/RT is a highly malignant tumor occurring in the central nervous system.
  • The tumor is characterized by a heterogeneous histologic and immunohistochemical phenotype.
  • It needs to be distinguished from a number of central nervous system tumors, including medulloblastoma, primitive neuroectodermal tumor, germ cell neoplasm and rhabdoid meningioma.
  • [MeSH-major] Brain Neoplasms / pathology. Rhabdoid Tumor / pathology. Teratoma / pathology
  • [MeSH-minor] Actins / analysis. Adult. Antigens, CD / analysis. Cell Adhesion Molecules / analysis. Child, Preschool. Desmin / analysis. Glial Fibrillary Acidic Protein / analysis. Humans. Immunohistochemistry. Keratins / analysis. Male. Mucin-1 / analysis. Muscle, Smooth / chemistry. Neurofilament Proteins / analysis. S100 Proteins / analysis. Vimentin / analysis

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17069697.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Desmin; 0 / Glial Fibrillary Acidic Protein; 0 / Mucin-1; 0 / Neurofilament Proteins; 0 / S100 Proteins; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


81. Liu HY, Zhang XL, Chen YP, Qiu SJ: [Characteristic imaging features of primary central nervous system lymphoma in comparison with pathological findings]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Feb;29(2):333-6
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristic imaging features of primary central nervous system lymphoma in comparison with pathological findings].
  • OBJECTIVE: To investigate the imaging features of primary central nervous system lymphoma (PCNSL).
  • RESULTS: Among the 13 patients with PCNSL, 11 were identified to have solitary tumor foci and the other 2 had multiple lesions.
  • Supratentorial tumors were found in 9 patients, infratentorial tumors in 3 patients, and both supratentorial and infratentorial tumors in 1 patient.
  • In 6 cases, the tumor presented isodensity or slight hypodensity on plain CT images, with mild or moderate enhancement after contrast agent injection.
  • Pathologically, the tumors appeared pinkish or grey-white, soft, with rich blood supply and without capsules.
  • The tumor cells were found to cluster around the blood vessels under microscope.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma / diagnosis. Lymphoma / pathology. Magnetic Resonance Imaging. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Supratentorial Neoplasms / diagnosis. Supratentorial Neoplasms / pathology. Young Adult

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19246316.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


82. Koh ES, Nichol A, Millar BA, Ménard C, Pond G, Laperriere NJ: Role of fractionated external beam radiotherapy in hemangioblastoma of the central nervous system. Int J Radiat Oncol Biol Phys; 2007 Dec 1;69(5):1521-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of fractionated external beam radiotherapy in hemangioblastoma of the central nervous system.
  • PURPOSE: To assess the clinical outcomes and toxicity in patients receiving fractionated external beam radiotherapy (EBRT) for hemangioblastoma of the central nervous system, treated at two Canadian radiation oncology institutions.
  • METHODS AND MATERIALS: Between January 1980 and December 2004, the data of all patients receiving EBRT for central nervous system hemangioblastoma were retrospectively reviewed.
  • The patient, tumor, and treatment characteristics were collected and overall survival, disease-free survival, and EBRT-related toxicities assessed.
  • [MeSH-major] Cerebellar Neoplasms / radiotherapy. Hemangioblastoma / radiotherapy. Spinal Cord Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. British Columbia. Disease-Free Survival. Dose Fractionation. Female. Humans. Male. Middle Aged. Ontario. Radiation Injuries / complications. Retrospective Studies. von Hippel-Lindau Disease / complications

  • Genetic Alliance. consumer health - Hemangioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17869023.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


83. Tropinskaia OF, Serova NK, Aronov MS, Kobiakov GL: [Malignant lymphoma of the central nervous system and eye]. Vestn Oftalmol; 2008 Jan-Feb;124(1):14-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant lymphoma of the central nervous system and eye].
  • Intraocular lymphoma was encountered in 11.4% of the 79 examined patients with malignant lymphoma of the central nervous system.
  • [MeSH-major] Brain Neoplasms / diagnosis. Eye Neoplasms / diagnosis. Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / administration & dosage. Biopsy. Child. Diagnosis, Differential. Drug Administration Routes. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Methotrexate / administration & dosage. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed. Vitreous Body

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18318202.001).
  • [ISSN] 0042-465X
  • [Journal-full-title] Vestnik oftalmologii
  • [ISO-abbreviation] Vestn Oftalmol
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


84. Jahnke K, Thiel E, Martus P, Schwartz S, Korfel A: Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. Ann Hematol; 2006 Jan;85(1):45-50
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system.
  • The aim of this retrospective single-center study was to analyze the clinical characteristics and outcome of non-Hodgkin lymphoma (NHL) patients with central nervous system (CNS) involvement and to identify prognostic factors for survival.
  • We searched our hospital records for NHL patients diagnosed with CNS involvement from 1982 to 2004, and 43 patients were identified.
  • Treatment of CNS lymphoma included intrathecal chemotherapy in 33 patients (77%), systemic chemotherapy in 25 (58%), and radiotherapy in 16 (37%).
  • Twenty-six patients showed a CNS response.
  • The median survival after CNS manifestation was 5 months (range 2 days-82.5+months).
  • Low lactate dehydrogenase (LDH) at CNS manifestation and a CNS response to therapy were favorable independent prognostic factors for survival in multivariate analysis (p = 0.051 and p < 0.0005, respectively), whereas a young age at initial diagnosis, initial CNS involvement, an initially normal LDH, and high-dose chemotherapy for CNS involvement were significant in univariate analysis.
  • In conclusion, long-term survival can be achieved in patients with secondary CNS lymphoma.
  • LDH at CNS manifestation and a CNS response to therapy were significantly associated with survival.
  • [MeSH-major] Central Nervous System Neoplasms / mortality. Lymphoma, Non-Hodgkin / mortality
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. L-Lactate Dehydrogenase / metabolism. Male. Middle Aged. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16132909.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


85. Levy O, Deangelis LM, Filippa DA, Panageas KS, Abrey LE: Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. Cancer; 2008 Jan 1;112(1):151-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-6 predicts improved prognosis in primary central nervous system lymphoma.
  • BACKGROUND: In systemic non-Hodgkin lymphoma (NHL), tumors that resemble germinal center B-cells are less aggressive than tumors that resemble postgerminal center B-cells.
  • However, the value of B-cell differentiation markers in primary central nervous system lymphoma (PCNSL) is less clear.
  • There was a nonsignificant trend toward improved overall survival in patients who had bcl-6 expressing tumors.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma / diagnosis. Proto-Oncogene Proteins c-bcl-6 / analysis
  • [MeSH-minor] Adult. Age Factors. Aged. Biomarkers, Tumor / analysis. Disease-Free Survival. Female. Humans. Immunohistochemistry. Immunophenotyping. Male. Middle Aged. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17999414.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-6
  •  go-up   go-down


86. Yilmaz M, Erkutlu I, Kilciksiz S, Pehlivan M, Okan V, Alptekin M, Sari I: Modified IDARAM chemotherapy regimen for primary central nervous system lymphoma: experience of three cases. Hematology; 2008 Apr;13(2):107-13
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modified IDARAM chemotherapy regimen for primary central nervous system lymphoma: experience of three cases.
  • The use of radiotherapy (RT) with chemotherapy has improved disease free survival and control in primary central nervous system lymphoma (PCNSL).
  • We have encountered three patients with histologically documented central nervous system lymphoma.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Lymphoma, B-Cell / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols. Cranial Irradiation. Cytarabine / therapeutic use. Dexamethasone. Humans. Idarubicin. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616878.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 7S5I7G3JQL / Dexamethasone; ZRP63D75JW / Idarubicin
  •  go-up   go-down


87. Kim EY, Kim SS: Magnetic resonance findings of primary central nervous system T-cell lymphoma in immunocompetent patients. Acta Radiol; 2005 Apr;46(2):187-92
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance findings of primary central nervous system T-cell lymphoma in immunocompetent patients.
  • PURPOSE: To describe the MR findings of primary central nervous system T-cell lymphoma (T-PCNSL) in immunocompetent patients.
  • The number, location, shape, enhancement pattern, and signal intensity of the tumors were determined.
  • All tumors showed iso- to low T1 and iso- to slightly high T2 signal intensity to the adjacent gray matter.
  • The lower rCBV ratio of the tumor might be helpful in differentiating T-PCNSL from other brain tumors such as high-grade glioma.
  • [MeSH-major] Brain Neoplasms / pathology. Immunocompetence. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Adolescent. Adult. Cerebrovascular Circulation / physiology. Diagnosis, Differential. Diffusion Magnetic Resonance Imaging. Female. Humans. Male. Middle Aged. Reproducibility of Results

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902895.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


88. Sakurada K, Saino M, Mouri W, Sato A, Kitanaka C, Kayama T: Nestin expression in central nervous system germ cell tumors. Neurosurg Rev; 2008 Apr;31(2):173-6; discussion 176-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nestin expression in central nervous system germ cell tumors.
  • Central nervous system (CNS) germ cell tumors constitute a unique class of rare tumors that mainly affect children and adolescents.
  • These tumors are believed to originate from displaced primordial germ cells.
  • Recently, results of treatment of germ cell tumors have improved with use of radiotherapy and combination chemotherapy.
  • However, some tumors have proven refractory to intensive treatment with surgery, radiation, and combination chemotherapy.
  • Nestin is an intermediate filament protein expressed in undifferentiated cells during CNS development and in CNS tumors and is used as a marker of immature elements of tumors, including brain tumor stem cells.
  • In this study, we examined for the first time nestin expression in 19 CNS germ cell tumors (nine pure germinomas, five germinomas with syncytiotrophoblastic giant cells, one yolk sac tumor, one choriocarcinoma, one embryonal carcinoma, and two mature teratomas).
  • Clinically, nestin-negative tumors did not exhibit dissemination, while all tumors that exhibited dissemination also strongly expressed nestin protein.
  • These findings suggest that the detection of nestin expression could be useful in the management of CNS germ cell tumors, as an auxiliary predictor of dissemination and/or progression.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Central Nervous System Neoplasms / genetics. Intermediate Filament Proteins / biosynthesis. Intermediate Filament Proteins / genetics. Neoplasms, Germ Cell and Embryonal / genetics. Nerve Tissue Proteins / biosynthesis. Nerve Tissue Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Choriocarcinoma / genetics. Choriocarcinoma / metabolism. Choriocarcinoma / pathology. Endodermal Sinus Tumor / genetics. Endodermal Sinus Tumor / metabolism. Endodermal Sinus Tumor / pathology. Female. Germinoma / genetics. Germinoma / metabolism. Germinoma / pathology. Giant Cell Tumors / genetics. Giant Cell Tumors / metabolism. Giant Cell Tumors / pathology. Humans. Hypopituitarism / etiology. Immunoenzyme Techniques. Magnetic Resonance Imaging. Male. Nestin. Teratoma / genetics. Teratoma / metabolism. Teratoma / pathology. Vision Disorders / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18092184.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


89. D'Haene N, Catteau X, Maris C, Martin B, Salmon I, Decaestecker C: Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas. Br J Haematol; 2008 Feb;140(4):402-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas.
  • Recently, considerable attention has been focused on the identification of clinically relevant prognostic markers for primary central nervous system lymphomas (PCNSL).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Central Nervous System Neoplasms / metabolism. Endothelium, Vascular / pathology. Galectin 3 / metabolism. Lymphoma, Non-Hodgkin / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Galectin 1 / metabolism. Humans. Hyperplasia / metabolism. Immunocompetence. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Proteins / metabolism. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18081894.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 1; 0 / Galectin 3; 0 / Neoplasm Proteins
  •  go-up   go-down


90. Assanasen T, Shuangshoti S, Nilyai S, Wannakrairot P, Ruangvejvorachai P, Sawatdee R, Sangprakarn S: Overexpression of c-Myc in primary central nervous system lymphoma of Thais. J Med Assoc Thai; 2006 Sep;89 Suppl 3:S40-6
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of c-Myc in primary central nervous system lymphoma of Thais.
  • BACKGROUND: c-Myc protooncogenes have been implicated in the tumourigenesis of extracerebral lymphomas, however only afew studies on this oncogenic molecule have been available for primary central nervous system lymphoma (PCNSL).
  • OBJECTIVE: To determine the prevalence ofprotein overexpression and gene amplification of c-Myc in PCNSL and to correlate with histological and immunophenotypic subtypes of malignant lymphoma according to WHO classification of tumors of haematopoietic and lymphoid tissue 2001.
  • [MeSH-major] Central Nervous System Neoplasms / metabolism. Lymphoma / metabolism. Proto-Oncogene Proteins c-myc / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Gene Amplification. Gene Expression Regulation, Neoplastic. Humans. Immunocompetence. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Prevalence. Thailand

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17718267.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


91. Ulu EM, Töre HG, Bayrak A, Güngör D, Coşkun M: MRI of central nervous system abnormalities in childhood leukemia. Diagn Interv Radiol; 2009 Jun;15(2):86-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI of central nervous system abnormalities in childhood leukemia.
  • PURPOSE: To document the imaging abnormalities seen in the central nervous system (CNS) in childhood leukemia or as complications of its treatment.
  • The first group consisted of patients with CNS abnormalities detected prior to or during treatment, or within three months after completion of treatment.
  • Patients with CNS complications detected by MRI three months following completion of treatment were included in the second group.
  • RESULTS: Among the 15 children, six had two or more different CNS abnormalities.
  • Three months after completion of treatment, three patients had CNS complications including radiation necrosis and secondary brain tumor, osteomyelitis of the L3 vertebra, and meningeal leukemia.
  • CONCLUSION: The wide spectrum of CNS abnormalities that occur during and after treatment for leukemia is related to leukemia and to the treatment method.
  • [MeSH-major] Central Nervous System Diseases / diagnosis. Central Nervous System Neoplasms / diagnosis. Leukemia / complications. Magnetic Resonance Imaging. Neoplasms, Second Primary / diagnosis
  • [MeSH-minor] Adolescent. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Child. Combined Modality Therapy / adverse effects. Female. Humans. Infant. Male. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19517377.001).
  • [ISSN] 1305-3612
  • [Journal-full-title] Diagnostic and interventional radiology (Ankara, Turkey)
  • [ISO-abbreviation] Diagn Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


92. Schmidt LS, Grell K, Frederiksen K, Johansen C, Schmiegelow K, Schüz J: Seasonality of birth in children with central nervous system tumours in Denmark, 1970-2003. Br J Cancer; 2009 Jan 13;100(1):185-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seasonality of birth in children with central nervous system tumours in Denmark, 1970-2003.
  • We investigated possible seasonal variation of births among children <20 years with a central nervous system tumour in Denmark (N=1640), comparing them with 2,582,714 children born between 1970 and 2003.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. Seasons
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Denmark. Ependymoma / epidemiology. Female. Humans. Infant. Infant, Newborn. Male. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroepidemiology. 2006;27(2):57-60 [16847388.001]
  • [Cites] Brain Res Brain Res Rev. 2005 Dec 1;50(1):69-85 [15982744.001]
  • [Cites] Neurology. 2006 Dec 12;67(11):1979-83 [17159104.001]
  • [Cites] J Natl Cancer Inst. 2007 May 16;99(10):790-800 [17505074.001]
  • [Cites] N Engl J Med. 2007 Jul 19;357(3):266-81 [17634462.001]
  • [Cites] Neuroepidemiology. 2007;29(1-2):89-95 [17925600.001]
  • [Cites] Am J Epidemiol. 2008 Aug 15;168(4):366-73 [18579539.001]
  • [Cites] Br J Cancer. 2002 Apr 8;86(7):1070-7 [11953851.001]
  • [Cites] Br J Cancer. 2002 Sep 23;87(7):746-50 [12232758.001]
  • [Cites] Neurology. 2004 Jul 27;63(2):276-81 [15277620.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6404-28 [15322514.001]
  • [Cites] Br J Prev Soc Med. 1975 Mar;29(1):18-21 [1137765.001]
  • [Cites] Neurol Med Chir (Tokyo). 1982 Dec;22(12):1002-8 [6188966.001]
  • [Cites] N Engl J Med. 1993 Aug 19;329(8):536-41 [8336753.001]
  • [Cites] Cancer Causes Control. 1996 Jul;7(4):437-48 [8813432.001]
  • [Cites] Int J Cancer. 1996 Dec 11;68(6):759-65 [8980180.001]
  • [Cites] Int J Cancer. 1998 Aug 12;77(4):498-503 [9679748.001]
  • [Cites] Eur J Epidemiol. 1998 Jul;14(5):471-5 [9744679.001]
  • [Cites] Cancer. 1999 May 1;85(9):2077-90 [10223251.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):627-32 [10433955.001]
  • [Cites] Paediatr Perinat Epidemiol. 2001 Oct;15(4):338-45 [11703681.001]
  • [Cites] Neurology. 2005 Apr 12;64(7):1317; author reply 1317 [15824382.001]
  • [Cites] Arch Environ Health. 2004 Jan;59(1):26-30 [16053206.001]
  • [Cites] Ugeskr Laeger. 2005 Oct 3;167(40):3782-5 [16221395.001]
  • [Cites] Chronobiol Int. 2006;23(5):1047-52 [17050217.001]
  • (PMID = 19066608.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2634676
  •  go-up   go-down


93. Betlej M, Czepko R, Lopatka P, Danilewicz B, Uhl H: [Diagnosis and operative treatment cavernous angiomas of the central nervous system]. Przegl Lek; 2006;63(2):61-3
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and operative treatment cavernous angiomas of the central nervous system].
  • The aim of this study is to present the diagnostic methods of CA of the central nervous system (CNS), indications for surgery and assessment of its outcome.
  • CONCLUSIONS:. (1) direct surgical outcome in CA of the CNS is good and very good in the majority of cases;.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Hemangioma, Cavernous, Central Nervous System / diagnosis. Hemangioma, Cavernous, Central Nervous System / surgery
  • [MeSH-minor] Adult. Epilepsy / etiology. Epilepsy / prevention & control. Female. Humans. Male. Middle Aged. Neurosurgical Procedures. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16967711.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


94. Catapano D, Muscarella LA, Guarnieri V, Zelante L, D'Angelo VA, D'Agruma L: Hemangioblastomas of central nervous system: molecular genetic analysis and clinical management. Neurosurgery; 2005 Jun;56(6):1215-21; discussion 1221
Hazardous Substances Data Bank. (L)-ARGININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemangioblastomas of central nervous system: molecular genetic analysis and clinical management.
  • OBJECTIVE: Hemangioblastomas of the central nervous system (CNS) are benign neoplasms that may occur sporadically or in association with von Hippel-Lindau (VHL) disease.
  • We investigated the frequency of VHL germline mutation in patients with symptomatic CNS hemangioblastoma without evidence of VHL disease to define the role of molecular genetic analysis in the management of such patients and their relatives.
  • METHODS: We analyzed 14 patients (6 female and 8 male; mean age, 43.5 yr) with no family history and no other clinical manifestations of VHL disease who had been operated on for symptomatic CNS hemangioblastoma.
  • CONCLUSION: Molecular genetic analysis is a safer and more specific instrument to confirm or exclude VHL disease in patients with CNS hemangioblastoma, a negative family history, or absence of other known manifestations of the disease.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Hemangioblastoma / genetics. Molecular Biology. Von Hippel-Lindau Tumor Suppressor Protein / genetics
  • [MeSH-minor] Adult. Aged. Arginine / genetics. DNA Mutational Analysis / methods. Exons. Female. Humans. Leucine / genetics. Magnetic Resonance Imaging / methods. Male. Middle Aged. Mutation, Missense. Proline / genetics. Retrospective Studies. Tryptophan / genetics. von Hippel-Lindau Disease / genetics

  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. L-Leucine .
  • Hazardous Substances Data Bank. (L)-Tryptophan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918937.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8DUH1N11BX / Tryptophan; 94ZLA3W45F / Arginine; 9DLQ4CIU6V / Proline; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein; GMW67QNF9C / Leucine
  •  go-up   go-down


95. Ponzoni M, Berger F, Chassagne-Clement C, Tinguely M, Jouvet A, Ferreri AJ, Dell'Oro S, Terreni MR, Doglioni C, Weis J, Cerati M, Milani M, Iuzzolino P, Motta T, Carbone A, Pedrinis E, Sanchez J, Blay JY, Reni M, Conconi A, Bertoni F, Zucca E, Cavalli F, Borisch B, International Extranodal Lymphoma Study Group: Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas. Br J Haematol; 2007 Aug;138(3):316-23
Genetic Alliance. consumer health - B-Cell Lymphomas.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas.
  • Well-established histopathological prognostic factors are lacking in primary central nervous system (CNS) lymphomas (PCNSL).
  • [MeSH-major] Central Nervous System Neoplasms / immunology. Lymphoma, B-Cell / immunology. T-Lymphocytes / pathology
  • [MeSH-minor] Adult. Aged. B-Lymphocytes / pathology. Blood Vessels. Female. Humans. Lymphocyte Activation. Male. Middle Aged. Multivariate Analysis. Pericytes / pathology. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17555470.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


96. Karantanis D, O'eill BP, Subramaniam RM, Witte RJ, Mullan BP, Nathan MA, Lowe VJ, Peller PJ, Wiseman GA: 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. Nucl Med Commun; 2007 Nov;28(11):834-41
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients.
  • OBJECTIVE: To determine the value of F-FDG PET/CT in the different manifestations of primary central nervous system lymphoma (PCNSL) in HIV-negative patients.
  • PET/CT examinations were reviewed by two experienced readers and evaluated for each possible anatomical site of nervous system involvement: cerebral, spinal/nerve and ocular.
  • [MeSH-major] Central Nervous System Neoplasms / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Cohort Studies. Female. Fluorodeoxyglucose F18. HIV Seronegativity. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Neoplasm Recurrence, Local. Positron-Emission Tomography. Radiopharmaceuticals. Retrospective Studies. Rituximab

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17901765.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 4F4X42SYQ6 / Rituximab; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


97. Shibamoto Y, Ogino H, Hasegawa M, Suzuki K, Nishio M, Fujii T, Kato E, Ishihara S, Sougawa M, Kenjo M, Kawamura T, Hayabuchi N: Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys; 2005 Jul 1;62(3):809-13
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s.
  • PURPOSE: Results of radiation therapy for primary central nervous system lymphoma (PCNSL) were poor in the 1970-1980s, with most reported 5-year survival rates being less than 10%.
  • The data were analyzed in relation to patient and tumor characteristics.
  • Multiple tumors were seen in 34%.
  • The median radiation dose to the tumor site was 50 Gy (range, 8-74 Gy).
  • [MeSH-major] Central Nervous System Neoplasms / radiotherapy. Lymphoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Multivariate Analysis. Survival Rate / trends

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936564.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


98. Ngan KW, Jung SM, Lee LY, Chuang WY, Yeh CJ, Hsieh YY: Immunohistochemical expression of OCT4 in primary central nervous system germ cell tumours. J Clin Neurosci; 2008 Feb;15(2):149-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of OCT4 in primary central nervous system germ cell tumours.
  • The aim of this study was to evaluate the role of OCT4 expression in the diagnosis of primary central nervous system (CNS) pure and mixed GCT.
  • Seventeen formalin-fixed, paraffin-embedded tissues of primary CNS GCT were immunohistochemically studied.
  • In conclusion, we found that OCT4 immunostaining is a useful diagnostic tool to assist in the identification of primary CNS embryonal carcinoma and germinoma.
  • In CNS mixed GCT, OCT4 expression can be detected provided that the components include embryonal carcinoma and/or germinoma.
  • [MeSH-major] Central Nervous System Neoplasms / metabolism. Neoplasms, Germ Cell and Embryonal / metabolism. Octamer Transcription Factor-3 / metabolism
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17997317.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human
  •  go-up   go-down


99. Swain RS, Tihan T, Horvai AE, Di Vizio D, Loda M, Burger PC, Scheithauer BW, Kim GE: Inflammatory myofibroblastic tumor of the central nervous system and its relationship to inflammatory pseudotumor. Hum Pathol; 2008 Mar;39(3):410-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor of the central nervous system and its relationship to inflammatory pseudotumor.
  • Inflammatory myofibroblastic tumor (IMT) is a distinctive spindle cell lesion and occurs primarily in soft tissue.
  • IMT in the central nervous system (CNS) is rare, its characteristics are poorly defined, and its relation to similar tumors at other sites is unclear.
  • To better characterize IMT within the CNS, we studied clinicopathologic features of 6 IMTs and compared them with 18 nonneoplastic lesions originally classified as IP.
  • All tumors were composed of neoplastic spindle cells and a variable amount of inflammatory infiltrate.
  • We suggest that IMT in the CNS is distinct from the nonneoplastic IP, and distinguishing IMT from nonneoplastic lesions should enable better decisions for patient management.
  • [MeSH-major] Central Nervous System Neoplasms / classification. Central Nervous System Neoplasms / pathology. Granuloma, Plasma Cell / classification. Granuloma, Plasma Cell / pathology. Myofibroma / classification. Myofibroma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infant. Male. Middle Aged

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18261625.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Jahnke K, Korfel A, Martus P, Weller M, Herrlinger U, Schmittel A, Fischer L, Thiel E, German Primary Central Nervous System Lymphoma Study Group (G-PCNSL-SG): High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol; 2005 Mar;16(3):445-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma.
  • We evaluated HDMTX-related toxicity with special regard to age distribution in patients with primary central nervous system lymphoma (PCNSL) in a phase IV multicenter trial.

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15653703.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase IV; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement